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Abstract: The primary aim of the current study was to investigate the
effects of attributions on fear reduction by having participants undergo exposure-
based treatment in the context of an inactive medication that they were led to
believe made the exposures easier (informed that the medication had a
relaxing/sedating side-effect profile) or made the exposures more difficult
(informed that the medication had an activating side-effect profile). Participants
(N = 95) displaying marked claustrophobic fear were randomly assigned to 1 of 6
conditions: (a) Exposure Only (EO), (b) Exposure + Pill Placebo + Arousal
v
Instruction (EPA attribution for pill interference), (c) Exposure + Pill Placebo +
Neutral Instruction (EPN), (d) Exposure + Pill Placebo + Relaxation Instruction
(EPR attribution for pill facilitation), (e) credible psychological placebo treatment
(PLT), or (f) wait-list (WL). Consistent with prediction, results showed that an
attribution for pill facilitation (EPR: relaxing/sedating instruction) interfered with
fear reduction and led to higher relapse. Contrary to prediction, an attribution for
pill interference (EPA: arousal instruction) did not outperform the other exposure
conditions. Clinically significant improvement rates at posttreatment were as
follows: EO = 73%, EPA = 75%, EPN = 78%, EPR = 76%, PLT = 60%, WL =
10%. Clinically significant improvement rates at follow-up were as follows: EO =
87%, EPA = 85%, EPN = 89%, EPR = 53%, PLT = 40%, WL = 30%. Relapse
rates at follow-up were as follows: EO=0%, EPA=0%, EPN=0%, and EPR=39%.
The deleterious effects of the relaxation instructions were fully mediated by
attributions about the helpful effects of the medication reducing the variance
accounted for by treatment from 30% to 7%. Findings suggest the importance of
assessing attributions during combined exposure-based and pharmacological
treatments and attention to a slow medication taper and reapplication of exposure
during the taper.
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CHAPTER 1: INTRODUCTION 
The average anxiety disorder patient comes to treatment after having 
suffered with the disorder for 9 years and is likely taking medication. Fortunately, 
cognitive behavioral therapy (CBT) demonstrates some of the strongest effect 
sizes in the literature for treating anxiety. However, after successful CBT 
treatment many of these patients later relapse when they discontinue their 
medication. This is perplexing given the low relapse rates in similar patients who 
do not take medication during CBT. One possible explanation occurred to me 
while working with such patients. During the course of treatment patients would 
frequently ask, “I’m feeling much better lately, now what is going to happen if I 
stop taking my medication?” Clearly this patient is concerned that their treatment 
gains may partly be due to the medication and fear that discontinuing the 
medication may herald a return of symptoms. This question makes one wonder 
what role medication attributions play in explaining relapses. Is it possible that if 
a patient attributes their treatment gains to the medication that this will interfere 
with fear reduction? Preliminary studies suggest the answer could be yes. In this 
way patients may learn conditional safety – I’m ok as long as I take my 
medication. However, to date no study has experimentally manipulated 
attributions to test a causal relationship.        
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This study was designed to experimentally test the hypothesis that patients 
who undergo exposure-based treatment for anxiety while on medication may fair 
poorer at follow-up if they are medication free and attribute their gains to the 
medication rather than their own efforts and the exposure treatment. To test this 
hypothesis the study was designed to randomly assign participants to attribution 
for pill facilitation, attribution for pill interference, or a neutral attribution. We 
chose to conduct the study in the context of claustrophobia due to the fact that 
exposure treatment for this condition may be effective in only one session.  
 First, we describe the nature and treatment of specific phobias. Next we 
discuss the successes, but more importantly the failures of exposure-based 
treatment for anxiety disorders when they are paired with medication taking. 
Finally we describe a test of attributions as a possible explanation for treatment 
failure in combined treatment. 
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1.1 Defining Features of Specific Phobias 
1.1.1 Nature and Epidemiology 
According to the DSM-IV (American Psychiatric Association, 1994), the 
central feature of a specific phobia is a marked and persistent fear of a specific 
object or situation (e.g., animals, storms, seeing  blood, enclosed spaces).  
Although recognizing that the fear is unrealistic and excessive, specific phobia 
sufferers avoid phobic situations or endure them with significant anxiety and 
distress. For those under 18-years old, the symptoms must last at least 6-months.  
Moreover, a DSM-IV diagnosis of specific phobia warrants that the fear and 
related avoidance cause significant interference with the normal routine, 
occupational functioning, or social activities and relationships.   
 The DSM-IV (American Psychiatric Association, 1994) makes a 
distinction between five subtypes: Animal Type (e.g., snakes, spiders, dogs), 
Natural Environmental Type (e.g., heights, storms, water), Blood-Injection-Injury 
Type, Situational Type (e.g., enclosed spaces, airplanes, elevators), and Other 
Type (e.g., choking, vomiting, or contracting an illness; in children, loud sounds 
or clowns).  
Anxiety disorders have been estimated to be the most prevalent mental 
disorder.  The National Comorbidity Survey Replication (NCS-R; Kessler, 
Berglund, Demler, Jin, & Walters, 2005; Kessler, Chiu, Demler, & Walters, 2005) 
with a sample of 9,282 English-speaking respondents aged 18 years or older and 
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based on DSM-IV criteria (American psychiatric Association, 1994) showed that 
29% of the sample reported a lifetime history of at least one anxiety disorder 
(21% for any mood disorder) and 18% reported an anxiety disorder in the past 12 
months (10% for any mood disorder). 
Estimates of the lifetime and 1-year prevalence rates for specific phobias 
according to the DSM-IV from the National Comorbidity Survey Replication are 
about 13% and 9% respectively (American Psychiatric Association, 1994; 
Kessler, Berglund, Demler, Jin, & Walters, 2005; Kessler, Chiu, Demler, & 
Walters, 2005).  A similar lifetime prevalence figure of 11% was reported in the 
earlier, ECA study (Eaton et al., 1991).  However, anyone housing animals for 
treatment purposes finds that far more than 1 in 10 individuals express discomfort 
(in the laboratory alone).  In fact, this is what other research suggests.  The 
discrepancy lies in the definition and sample studied.  Some studies have relied on 
a cutoff score on a continuum of severity in a community sample.  For example, 
Agras, Sylvester, and Oliveau (1969) found that 25% of those interviewed in 
Burlington, Vermont reported an intense fear of snakes and 39% reported at least 
mild fear.  In another community sample, Costello (1982) reported a higher 
prevalence of phobias (19%) in a sample of 449 women.   
Specific phobias are approximately two to four times as common in 
women than in men.  The lifetime and 1-month female-male prevalence ratios, 
respectively, are 2.3:1.0 (z=7.4, p<.05) and 3.8:1.0 (z=7.2, p<.05) (Magee, Eaton, 
Wittchen, McGonagle, & Kessler, 1996).  The age of onset is most often in 
childhood (with the exception of claustrophobia having a mean onset age of 20-
5
years old) (Craske, 1999; Öst, 1987).  More specifically, the age of onset for 
specific phobias typically ranges between an approximate mean of 4.4-years-old 
to 22.7-years-old (Marks and Gelder, 1966; Liddell and Lyons, 1978; Sheehan, 
Sheehan, and Minichiello, 1981; Thyer, Parrish, Curtis, Nesse, and Cameron, 
1985). If phobias are defined as intense fears (endorsing “Terror” on fear items), 
an age pattern emerges (Kirkpatrick, 1984).  Namely, as people approach old age, 
fears of heights and water increase, while fears of animals and insects decrease. 
Phobia prevalence appears to be inversely related to education level and is 
higher among Hispanic populations, the unemployed (students, homemakers, etc), 
and those living with their parents or legal guardians (Magee, Eaton, Wittchen, 
McGonagle, & Kessler, 1996).  In addition, phobias are equally distributed across 
income, region of the country, and urbanicity. 
The course of specific phobias tends to be chronic with a low probability 
of spontaneous remission.  The Munich Follow-up Study followed 1,366 subjects 
in the community from 1974 to 1981 and estimated that only 17 to 30% of the 
anxiety patients (n=77) experienced symptom remission (Wittchen, 1988).  In 
addition, a study of patients seeking treatment for specific phobias suggested that 
participants had suffered from the fear for an average of 21-years, which is 
significantly higher than for the average pre-treatment duration of agoraphobic 
concerns (Öst, 1987). 
Most people (83.4%) with a specific phobia report at least one other 
lifetime disorder (Magee, Eaton, Wittchen, McGonagle, & Kessler, 1996).  The 
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most common comorbid conditions reported are: another anxiety disorder 
(68.7%), a mood disorder (46.8%), or substance-related disorders (39.4%).   
1.1.2 Indirect and Direct Costs of Illness 
The staggering costs of anxiety disorders have been well documented. 
Using the data from the NCS, Greenberg et al. (1999) estimated the total costs of 
anxiety disorders at 63.1 billion in 1998 dollars. This amount comprised medical 
treatment costs, psychiatric treatment costs, indirect workplace cost, and mortality 
costs.  Further, anxiety disorders account for 31% of total annual mental health 
care costs, exceeding those due to mood disorders (22%) and schizophrenia (20%) 
(Rice & Miller, 1993).  This figure is elevated due to the high prevalence, chronic 
nature, and functional impairment of anxiety.   
Anxiety disorders are also associated with an increased use of welfare, 
impaired marital and social functioning (Markowitz, Weissman, Ouellette, Lish, 
& Klerman, 1989), and impaired work productivity and employment status 
(Edlund & Swann, 1987).  Further, the quality of life in outpatients with panic 
disorder may be impaired as much as in patients with hypertension, diabetes type 
2, chronic obstructive pulmonary disease and osteoarthritis (Candilis, McLean, 
Otto, Manfro, Worthington, Paneva, Marzol, & Pollack, 1999). In addition, the 
suicide rate for inpatients with anxiety disorders is as high as for inpatients with 
mood disorders (Allgulander & Lavori, 1991).  In one study of people suffering 
from specific phobias, 34.2% reported significant interference, 30.2% sought 
professional help, and 8% reported lifetime use of medications for their phobias 
(Magee, Eaton, Wittchen, McGonagle, & Kessler, 1996).  Most patients, however, 
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do not seek help.  Only 16 to 40% of anxiety patients seek appropriate treatment 
due to avoidance and misdiagnosis, resulting in reduced work productivity, 
unnecessary medical procedures, and poor medication management (Angst & 
Dobler-Mikola, 1985; Thompson, Burns, Bartko, Boyd, Taube, & Bourbon, 1988; 
Pollard, Henderson, Frank & Margolis, 1989).  So the actual cost (including direct 
and indirect) of anxiety disorders may be much higher than estimated.   
1.2 Etiology of Specific Phobias 
Researchers currently agree that phobias are caused by a combination of 
both biological and environmental influences.  These influences may include 
conditioning (e.g., experiencing a car accident), modeling and vicarious 
experiences (e.g., seeing another person experience a car accident or repeatedly 
watching someone else behave fearfully while driving), and information 
transmission (e.g., reading or hearing about the dangers of driving; Rachman, 
1976, 1977).  Many studies have supported these methods of acquisition (e.g., Di 
Nardo et al., 1988; Ehlers, Hofmann, Herda, & Roth, 1994; McNally & Steketee, 
1985; Menzies & Clarke, 1993a; Merchelbach, Arntz, & de Jong, 1991; 
Merchelbach, Arntz, Arrindell, & de Jong, 1992; Merchelbach & Murris, 1997; 
Muris, Merchelbach, & Collaris, 1997; Muris, Steerneman, Merchelbach, & 
Meesters, 1996; Öst, 1985, 1991; Öst & Hugdal, 1985; Rimm, Janda, Lancaster, 
Nahl, & Dittmar, 1977; Townend, Dimigen, & Fung, 2000).  Specifically, 
evidence has accumulated for animal fears (Fredrikson, Annas, & Wik, 1997; 
King, Clowes-Hollins, & Ollendick, 1997; Merckelbach, Arntz, Arrindell, & de 
Jong, 1992; Merckelbach, Arntz, & de Jong, 1991; Öst & Hugdahl, 1981), 
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claustrophobia (Öst & Hugdahl, 1981), dental and blood, injury, and injection 
phobia (de Jongh, Muris, ter Hurst, & Duyx, 1995; Kleinknecht, 1994; Moore, 
Brodsgaard, & Brin, 1991; Öst, 1991; Öst & Hugdahl, 1985), and driving phobia 
(Munjack, 1984).  However, studies of environmental influences may lack 
reliability as they most often rely on retrospective self-reports.  For example, 
Taylor, Deane, and Podd (1999) found that participants often reported a different 
method of fear acquisition when asked one-year later.  In addition, between 5% 
and 25% of cases people are unable to recall how they acquired their fears 
(Rachman, 1990).  For these reasons, it is difficult to estimate the contribution of 
environmental factors. 
1.2.1 Biological Vulnerability 
Research on biological contributions to the etiology of mental disorders 
rely on family studies, twin studies, and identification of single and multiple gene 
effects.  These methods generate estimates of heritability and relative risk.  Uhl, 
Gold, and Risch (1997) state, “Heritability reflects the proportion of the total 
interindividual variation due to a gene variant, reflecting both the gene variant’s 
frequency in the population and the size of the effects that the gene variant causes.  
Sibling relative risk assesses the increased disease risk to siblings that share one-
half of the genes with affected probands.”  Heritability estimates are most often 
reported as either correlations (for continuous traits such as height or IQ) or 
concordances (for categorical traits such as mental disorders) (Willerman and 
Cohen, 1990).   
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FAMILY STUDIES.  Data suggest that specific phobias tend to run in 
families (Fredrikson, Annas, and Wik, 1997; Fyer, Mannuzza, Gallops, Martin, 
Aaronson, Gorman, Leibowitz, & Klein, 1990).  Further, there is a significant 
correlation between children’s fears and the extent to which their mothers exhibit 
their fears (Muris, Steerneman, Merckelback, and Meesters, 1996).  Fyer et al. 
(1990) investigated 49 first-degree relatives of probands and 119 relatives of 
controls and found a specific phobia relative risk of 3.3 (31% in relatives of 
probands vs. 13% in relatives of controls).  Likewise, Fredrickson et al. (1997) 
also found an increased risk in relatives of probands compared to controls.  
However, due to the correlational nature of Family studies, these data offer little 
unique information on what is causing the higher than expected incidence of 
phobias within families. 
TWIN STUDIES. Heritability estimates in twin studies for anxiety range 
between 19 and 50% (Clifford, Hopper, Fulker, and Murray, 1984; Jardine, 
Martin, and Henderson, 1984; Kendler, Walters, Neale, Kessler, Heath, and 
Eaves, 1995; MacKinnon, Henderson, and Andrews, 1990).  For example, 
Kendler, Neale, Kessler, Heath, and Eaves (1992) found concordance rates for 
animal phobias among monozygotic and dizygotic twins of 26% and 11% 
respectively.  Similarly, they later found differential concordance rates for 
situational and blood-injection-injury phobias (Kendler, Karkowski, and Prescott, 
1999).  More specifically, they found heritability estimates of: animal 47%, 
blood/injury 59%, and situational 46%. 
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GENE IDENTIFICATION.  Studies of genetic contributions to mental 
disorders suggest two conclusions: (a) there may be a general gene for neurotic 
mental illness, and (b) unique environment may determine which mental disorder 
develops and when.  Kendler, Heath, Martin, & Eaves (1987) found that genetics 
accounted for 27% of the total variance in anxious and depressive symptoms.  
These studies tell us there is not a single vulnerability for developing an anxiety 
disorder.  Rather, there may be a general genetic vulnerability to develop either 
anxiety or depression (Kendler, Heath, Martin, & Eaves, 1987; Kendler, Neale, 
Kessler, Heath, & Eaves, 1992; Kendler, 1996).  Further, some research has 
demonstrated a shared genetic risk of developing multiple neurotic disorders with 
unique environment determining which disorder evolves (Kendler, Walters, 
Neale, Kessler, Heath, & Eaves, 1995).  More specifically, animal studies have 
determined that areas on chromosomes 1, 12, and 15 create a general tendency to 
be anxious (Flint, Corley, DeFries, Fulker, Gray, Miller, & Collins, 1995).  Future 
studies will help determine if this finding generalizes to humans. 
1.2.2 Conditioning Experiences (direct, traumatic) 
Direct or traumatic accounts of phobia etiology posit that people 
experience a fear reaction (UCR) in the presence of a particular situation or object 
(NS, e.g. a spider) paired with a noxious stimulus (UCS, a severe bite with 
respiratory distress).  Eventually, the person experiences fear (CR) from the 














































But according to this theory we would expect that the fear would simply 
extinguish after enough experiences with spiders in the absence of another serious 
bite.  This lead Mowrer (1960) to develop the two-factor theory whereby the fear 
is acquired through classical conditioning and then maintained by operant 
conditioning (escape/avoidance of spiders).  Rates of people reporting direct 
traumatic experiences with the phobic object or situation are as follows: animal 
fears = 26.7 to 67% (Fredrikson, Annas, & Wik, 1997; King, Clowes-Hollins, & 
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Ollendick, 1997; Merckelbach, Arntz, Arrindell, & de Jong, 1992; Merckelbach, 
Arntz, & de Jong, 1991), claustrophobia = 69% (Öst & Hugdahl, 1981), dental 
and blood, injury, and injection phobias = 49 to 69% (de Jongh, Muris, ter Horst, 
& Duyx, 1995; Kleinknecht, 1994; Moore, Brodsgaard, & Brin, 1991; Öst, 1991; 
Öst & Hugdahl, 1985), and fears of driving = 70% (Munjack, 1984).  Children 
report direct conditioning experiences more than any other acquisition pathway 
(40%; Muris, Merckelbach, & Collaris, 1997).   
 
1.2.3 Modeling or Vicarious Experiences 
 
Conditioning theories of phobias make sense given the face validity and 
success of behavioral interventions in treating them.  However, data are mixed 
supporting this theory as the only explanation for phobia development.  Rachman 
(1990) stated, “By 1977, it had become clear that conditioning theory was 
incomplete and that there was a need to identify other forms of fear acquisition”.  
Rates of people reporting modeling or vicarious experiences by type of phobia are 
as follows: animal fears = 28 to 71% (Fredrikson, Annas, & Wik, 1997; King, 
Clowes-Hollins, & Ollendick, 1997; Merckelbach, Arntz, Arrindell, & de Jong, 
1992; Merckelbach, Arntz, & de Jong, 1991), claustrophobia = 9% (Öst & 
Hugdahl, 1981), dental and blood, injury, and injection phobias = 12%  (de Jongh, 
Muris, ter Horst, & Duyx, 1995; Kleinknecht, 1994; Moore, Brodsgaard, & Brin, 
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1991; Öst, 1991; Öst & Hugdahl, 1985).  Children report modeling experiences in 
only 1% of cases (Muris, Merckelbach, & Collaris, 1997).   
1.2.4 Information Transmission 
Interestingly, people can even acquire irrational fears in the absence of 
direct or vicarious experience.  Misinformation regarding threats is also a popular 
reported mechanism of phobia onset.  Rates of people reporting information 
transmission by type of phobia are as follows: animal fears = 6.7 to 15% 
(Fredrikson, Annas, & Wik, 1997; King, Clowes-Hollins, & Ollendick, 1997; 
Merckelbach, Arntz, Arrindell, & de Jong, 1992; Merckelbach, Arntz, & de Jong, 
1991), claustrophobia = 11% (Öst & Hugdahl, 1981), dental and blood, injury, 
and injection phobias = 6%  (de Jongh, Muris, ter Horst, & Duyx, 1995; 
Kleinknecht, 1994; Moore, Brodsgaard, & Brin, 1991; Öst, 1991; Öst & Hugdahl, 
1985).  Children reported information transmission as the cause of their fear onset 
in 27% of cases (Muris, Merckelbach, & Collaris, 1997).   
 In summary, specific phobias appear to develop as a combination of 
biological vulnerability and experience.  See Figure 1 and Figure 2 for diagrams 
of the proposed etiology of specific phobia. 
 
14
Figure 1. A model of the various pathways to a specific phobia.  Source: Barlow 
(2002) 
15
Figure 2.  Summary of etiological factors contributing to the anxiety disorders. 
(Source: Craske, 1999) 
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1.3 Treatment Approaches for Specific Phobias 
1.3.2 Psychosocial 
1.3.2.1 Exposure-Based Treatment 
Exposure-based treatments are currently considered the treatments of 
choice for specific phobias.  They were first developed during the Second World 
War to treat combat PTSD (Wolpe, 1958, 1973).  Joseph Wolpe, a South African 
doctor, complained of the poor efficacy of psychodynamic therapy in treating 
what was then called “shell shock”.   He wrote to his mentor at Johannesburg and 
asked if he could return to develop a better treatment for anxiety disorders.  He 
first developed an animal model of neurotic anxiety by shocking cats in their 
cages based on previous work by Pavlov.  The cats were so frightened that they 
would starve to death before eating in that cage again.  Wolpe then assumed that 
fear and feeding were incompatible.  Therefore, he assumed that if he could either 
raise the hunger or lower the anxiety of the cats, that the feeding response would 
take over and inhibit the fear.  Raising the hunger was not an option, as mentioned 
above, the cats were so frightened that they would starve before eating in the 
original cage.  He tried lowering the anxiety by changing the surroundings to be 
less like the learning environment.  This was done by changing cages, rooms, and 
furniture.  Success!  The cats would first look around hesitantly in the new 
surroundings, and then slowly begin to sniff at and eventually eat the meat pellets 
enthusiastically.  Next, he would add the furniture back and the same process 
occurred, first hesitation followed by voracious feeding.  Finally he had the cat 
eating back in the original room and in the original cage.  He came to call this 
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systematic desensitization and assumed the mechanism of change was due to what 
he coined “reciprocal inhibition”. 
Wolpe (1990) wrote, “We saw that strong evocations of anxiety were 
associated with inhibition of eating in food-deprived neurotic cats.  By contrast, 
eating took place when anxiety was relatively weak, and repeated eating resulted 
in manifest diminutions of the anxiety.  A reciprocally inhibitory relationship 
between the two responses was thus apparent…”.    Systematic desensitization 
involves teaching a patient to relax while exposing them to fearful images that 
gradually increased in intensity.  Today, exposure therapy may be defined as “A 
form of behaviour therapy in which individuals are required to confront the object 
or situation that they fear.  Typically, exposure is conducted in a structured and 
predictable manner and is repeated frequently.” (Antony and Swinson, 1996).  In 
addition, modern exposure therapy is most often conducted in-vivo whenever 
possible.  This is due to three primary reasons.  First, some studies have found in-
vivo exposure to be even more effective than imaginal exposure (Emmelkamp & 
Wessels, 1975; Mannion & Levine, 1984).  Second, in-vivo exposure requires 
fewer sessions.  Finally, data suggest there may be no additional benefit of adding 
relaxation training to exposure-based treatments (Öst, Lindahl, Sterner, & 
Jerremalm, 1984).   
To date, in-vivo exposure has been found to be effective for the treatment 
of  spiders (Hellstrom and Öst, 1995; Muris, Mayer, and Merckelbach, 1998; Öst, 
1996b; Öst, Ferebee, and Furmark, 1997; Öst, Salkovskis, and Hellstrom, 1991), 
snakes(Gauthier and Marshall, 1977; Hepner and Cauthen, 1975; Hepner and 
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Cauthen, 1975), rats (Foa, Blau, Prout, and Latimer, 1977), thunder and lightening 
(Öst, 1978), water (Menzies and Clarke, 1993b), heights (Baker, Cohen, and 
Saunders, 1973; Bourque and Ladouceur, 1980), flying (Beckham, Vrana, May, 
Gustafson, and Smith, 1990; Howard, Murphy, and Clarke, 1983; Öst, Brandberg, 
and Alm, 1997), enclosed spaces (Öst, Johansson, and Jerremalm, 1982; Craske, 
Mohlman, Yi, Glover, and Valeri, 1995; Powers, Smits, and Telch, 2004), 
choking (Greenberg, Stern, and Weilburg, 1988), dental fears (Gitin, Herbert, and 
Schmidt, 1996; Moore and Brodsgaard, 1994), blood (Öst, Fellenius, and Sterner, 
1991), and balloons (Houlihan, Schwartz, Miltenberger, and Heuton, 1993). 
1.3.2.2 Cognitive Therapy 
Although exposure-based treatments are considered to be the gold 
standard for treating specific phobias, cognitive approaches are also effective 
(Craske and Rowe, 1997).  Cognitive therapy can be defined as “A form of 
psychological treatment that attempts to change the thoughts which maintain a 
psychological disorder.  Examples of cognitive therapy techniques include 
cognitive restructuring, and coping self-statements.” (Antony and Swinson, 1996).  
Barlow and Durand (1995) further suggest that cognitive therapy is a “Treatment 
approach that involves identifying and altering negative thinking styles related to 
psychological disorders such as depression and anxiety and replacing them with 
more positive beliefs and attitudes and, ultimately, more adaptive behavior and 
coping styles”.  To date, cognitive therapy has proven effective for fears of 
enclosed spaces, spiders, snakes, and dental phobias (de Johgn, Muris, Horst, van 
Zuuren, Schoenmakers, and Makkes, 1995; Jerremalm, Janson, and Öst, 1986; 
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Getka and Glass, 1992; Craske, Mohlman, Yi, Glover, and Valeri, 1995; Booth 
and Rachman, 1992).  Although these studies suggested that cognitive 
interventions are effective, there was no evidence that they outperformed 
exposure-based treatments.  In addition, although the best outcomes may arise 
from in vivo exposure, recent mediation studies suggest that the mechanism of 
action in anxiety disorder treatment may be cognitive change (Smits, Powers, 
Cho, and Telch, 2004; Hofmann, in press).  This has led some to suggest that 
cognitive strategies may best be applied as an addition to exposure-based 
treatment to enhance outcome (Panzarella and Garlipp, 1999; Antony and 
Swinson, 2000). 
1.3.2.3 Alternative Approaches 
The two main alternative approaches to treating specific phobias include 
Eye Movement Desensitization and Reprocessing (EMDR) and applied tension 
for blood-injection-injury phobias.   
E.M.D.R. EMDR may be defined as “A new form of exposure therapy that 
has been a source of controversy in the behavior therapy literature.  While 
visualizing a feared image, individuals track the rapid movements of a therapist’s 
finger back and forth across the image.  Proponents of this approach believe that 
this is a unique therapeutic modality.  Critics argue that the effects of this 
technique are attributable entirely to the exposure component.” (Antony and 
Swinson, 1996).  EMDR was originally intended for the treatment of trauma 
(Shapiro & Forrest, 1997).  More recently, EMDR has been used to treat multiple 
anxiety disorders including specific phobias.  However, studies with phobic 
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participants suggest that: (a) EMDR is only effective in reducing subjective fear 
ratings and not behavioral performance (Muris, Merckelbach, Holdrinet, & 
Sijsenaar, 1998; Muris, Merckelbach, van Haaften, & Mayer, 1997), (b) the active 
component in EMDR is imaginal exposure (Sanderson & Carpenter, 1992), and 
(c) EMDR is not as effective as in vivo exposure (Muris, Merckelbach, Holdrinet, 
& Sijsenaar, 1998; Muris, Merckelbach, van Haaften, & Mayer, 1997). 
APPLIED TENSION.  Applied tension is a method of treating individuals 
with blood or injection phobias who tend to faint in the feared situation.  
Individuals are taught to tense the muscles of their body in order to raise their 
blood pressure and thereby prevent fainting in the presence of blood or injections.  
These skills are integrated with exposure to feared cues as they are practiced 
while confronting increasingly difficult situations.” (Antony and Swinson, 1996). 
1.3.3 Pharmacological Treatment 
There is good evidence that anxiety disorder patient respond well to 
monoamine oxidase inhibitors (MAO-I), selective serotonin reuptake inhibitors 
(SSRIs), tricyclic antidepressants, and benzodiazepines (Lydiard, Brawman-
Mintzer, & Ballenger, 1996; Pollack & Smoller, 1996). However, when such 
patients discontinue their medication relapse is common (Noyes, Garvey, Cook, 
& Samuelson, 1989; Noyes, Garvey, Cook, & Suelzer, 1991; Pollack & Smoller, 
1996). In addition, studies of panic disorder suggest that the longer a patient stays 
on their medication the better the outcome (Mavissikalian & Perel, 1993). To 
date, it is generally accepted that medications are not helpful for patients with 
specific phobias.  However, due to the disabling nature of specific phobias 
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(Magee, Eaton, Wittchen, McGonagle, & Kessler, 1996) and the fact that phobics 
react to CO2 similarly to those with panic disorder (Verburg, Griez, & Meijer, 
1994) have led some to believe that pharmacotherapy may be helpful.  Studies 
including benzodiazepines during standard treatment have suggested either no 
additional benefit (Whitehead, Robinson, Blackwell, and Stutz, 1978; Zoellner, 
Craske, Hussain, Lewis, and Echeveri, 1996) or only short term efficacy 
(Wilhelm and Roth, 1997; Thom, Sartory, and Johren, 2000).  Research on 
selective serotonin reuptake inhibitors (SSRIs) has also been conducted.  A case 
study of two participants being treatment for depression suggested that fluoxetine 
may have been effective in reducing fears of flying (Abene and Hamilton, 1998).  
In addition, Benjamin, Ben-Zion, Karbofsky, and Dannon (2000) conducted a 
preliminary double-blind placebo-controlled study of paroxetine for specific 
phobias (n=11).    Response rates for SSRI and placebo conditions were 60% and 
17% respectively.  Again, follow-up assessments were not conducted to determine 
the durability of the findings. 
1.3.4 Combined CBT and Pharmacotherapy   
Some researchers have considered the possibility that combining two 
effective treatments may enhance outcome (see Telch et al., 1985 and Telch & 
Lucas, 1994 for reviews). This lead to the investigation of combined cognitive 
behavioral and pharmacological treatment of anxiety disorders. Combination 
treatments have not been previously investigated in specific phobias. However, 
some studies show advantages of combined treatment over monotherapy after 
acute treatment for panic disorder (Barlow, Gorman, Shear, and Woods, 2000; 
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Marks et al., 1993), social phobia (Blomhoff, et al., 2001), OCD (Hohagen et al., 
1998; Cottraux et al., 1990), and GAD (Power, Simpson, Swanson, & Wallace, 
1990). Other studies do not show such an advantage (Franklin, Abramowitz, Bux, 
Zoellner, & Feeny, 2002; van Balkom et al., 1998; Gould et al., 1995). In 
addition, some studies suggest that the advantage of combined treatment may be 
accounted for by pill taking alone (Barlow et al., 2000; Power et al., 1990). 
However, long-term follow-up assessment suggests either no advantage or worse 
outcome for patients receiving combined treatment than those receiving CBT 
alone in panic disorder (Barlow, et al., 2000; Marks et al., 1993) and social phobia 
(Huag et al., 2003). Some authors have suggested that the deleterious effects of 
combined treatments may be due to attributions to the positive effects of 
medications that are lost once medication is discontinued (Basoglu, Marks, Kilic, 
& Brewin, 1994; Telch & Lucas, 1994). Although simultaneous combination 
treatment may prove less effective in the long run, there is some evidence that if 
patients fail to respond to one treatment that switching to the other modality may 
be helpful. For example, panic disorder and PTSD patients who fail to respond to 
an adequate trial of pharmacotherapy may later improve with CBT (Otto, Pollack, 
Paneva, & Zucker, 1999; Pollack, Otto, Kaspi, Hammerness, & Rosenbaum, 
1994; Otto et al., 2003). Likewise, panic patients that do not respond to CBT may 
later improve with pharmacotherapy (Kampman, Keijsers, Hoogduin, & 
Hendriks, 2002; Fava et al, 1997).  
 
23
CHAPTER 2: THE PRESENT STUDY 
2.1 Introduction 
Although combined treatment is frequently used in the treatment of 
anxiety disorders, evidence suggests that for at least some anxiety disorders, the 
combination of medication plus CBT may result in greater relapse (return of fear) 
than CBT alone (see Figure: Barlow, Gorman, Shear, & Woods, 2000; Marks et 
al., 1993). 
Relapse Rate (%)
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One possibility to account for this finding is that medication taking for anxiety 
disorders can be conceptualized within the framework of safety behavior theory. 
Anxiety-maintaining safety behaviors consist of actions that people perform when 
confronting fear-provoking situations in an effort to avert or attenuate a perceived 
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threat (Kamphuis & Telch, 1999). These behaviors may be covert (e.g., 
distraction) or overt (e.g., carrying or ingesting rescue medication). Paradoxically, 
the use of such safety-behaviors during exposure to fear-provoking cues has been 
shown to undermine the therapeutic efficacy of exposure (Sloan & Telch, 2001). 
Misattributional processes have been proposed as one possible factor accounting 
for the disruptive effects of safety behaviors on fear reduction during exposure 
(Salkovskis, 1991; Basoglu, Marks, Kilic, & Brewin, 1994; Telch, Tearnan & 
Taylor, 1983; Telch & Lucas, 1994).  
The overall goal of this study was to shed light on how attributional 
processes influence the effects of medication taking on subsequent return of fear 
(ROF) following exposure-based treatment. Participants meeting DSM-IV criteria 
for specific phobia with primary claustrophobia complaints were randomly 
assigned to one of six treatment conditions: (a) Exposure Only – no pill (EO), (b) 
Exposure + Pill Placebo with Arousal expectation (EPA), (c) Exposure + Pill 
Placebo with relaxation expectation (EPR), (d) Exposure + Pill Placebo with 
neutral expectation (EPN), (e) credible non-pill placebo treatment (PLT), or (f) 
wait-list (WL). In each of the exposure + pill conditions, participants were told 
that the pill was adomoxin (a fictional herbal supplement) and that one aim of the 
experiment is to test whether the pill enhances later recall memory for treatment. 
Upon completing treatment, participants in the EPR condition were told that 
adomoxin has a sedating side-effect profile that should have made the exposures 
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much easier; whereas participants in the EPA condition were told that adomoxin 
has an activating side-effect profile that should have made the exposures much 
more difficult. The EPN participants were told that they received a placebo 
(Vitamin C) that should have had no effect on their treatment. The effect of this 
pill attribution manipulation on return of fear at a one-week follow-up was 
assessed. 
2.2 Specific Aims  
 
Aim 1. Test the effects of an attributional manipulation in which 
participants were led to believe that their improvement during treatment occurred 
in the context of having taken a pill that made their exposure therapy less anxiety-
provoking and hence less difficult (i.e., I was able to conquer the chamber 
because I was sedated by the pill).  Hypothesis 1. The Exposure-Pill placebo + 
Relaxation instruction group (EPR) would show less overall improvement and 
higher return of fear at follow-up compared to the other exposure conditions. 
Aim 2. Test the effects of an attributional manipulation in which 
participants were led to believe that their improvement during treatment occurred 
in the context of having taken a pill that made their exposure therapy more 
anxiety-provoking and hence more difficult (i.e., I was able to conquer the 
chamber despite being “wired by the pill).    
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Hypothesis 2. The Exposure-Pill placebo + Arousal instruction group 
(EPA) would show greater overall improvement and lower return of fear at 
follow-up compared to the other exposure conditions. 
Aim 3. To further examine the specificity of exposure-based treatments 
through the inclusion of both placebo and waitlist conditions.   
 Hypothesis 3. All of the active-treatment groups would outperform the 
placebo treatment group.  The placebo group would outperform the wait-list 
condition. 
Aim 4. Determine if differences in response were mediated by attributions 
to the medication as a manipulation check. 
Hypothesis 4. The reduced fear reduction in the EPR condition would be 
mediated by medication attributions. 
Aim 5. To examine the potential moderating effects of age, gender, 
diagnostic status, and ethnicity in predicting participants’ response to treatment.   
Hypothesis 5. Based on previous studies from this laboratory, findings 
would not be moderated by age, gender, diagnostic status, or ethnicity. 
2.3 Background and Significance 
 
The continuum from worry through anxiety to panic, functions as an 
essential human motivator.  These are three responses to perceived threat that 
vary according to the proximal nature of the threat.  Anxiety motivates people to 
27
meet deadlines and panic may prevent immediate catastrophes.  As Howard 
Liddell (1949) stated, “Anxiety is the shadow of intelligence”.  Unfortunately, 
many Americans perceive threat that far exceeds any real danger to the point of 
significant avoidance and life impairment that can then be called an anxiety 
disorder.
The Problem.  Anxiety disorders cost the United States economy $63 
billion each year (Greenberg, Sisitsky, Kessler, Finkelstein, Berndt, Davidson, 
Ballenger, & Fyer, 1999).  This accounts for 31% of total annual mental health 
care costs, exceeding those due to mood disorders (22%) and schizophrenia (20%) 
(Rice & Miller, 1993).  This figure is elevated due to the high prevalence, chronic 
nature, and functional impairment of anxiety disorders.  Anxiety disorders have 
been estimated to be the most prevalent mental disorder.  The National Co-
morbidity Survey (NCS; Kessler et al., 1994) with a sample of 8,098 15 to 54-
year-olds and based on DSM-III-R criteria (American psychiatric Association, 
1987) showed that 25% of the sample reported a lifetime history of at least one 
anxiety disorder (20% for any mood disorder) and 17.2% reported an anxiety 
disorder in the past 12 months (11% for any mood disorder).  The probability of 
spontaneous remission of symptoms for patients with anxiety is low.  The Munich 
Follow-up Study followed 1,366 subjects in the community from 1974 to 1981 
and estimated that only 17 to 30% of the anxiety patients (n=77) experienced 
symptom remission (Wittchen, 1988).  Anxiety disorders predict increased use of 
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welfare, impaired marital and social functioning (Markowitz, Weissman, 
Ouellette, Lish, & Klerman, 1989), and impaired work productivity and 
employment status (Edlund & Swann, 1987).  In addition, the suicide rate for 
inpatients with anxiety disorders is as high as for inpatients with mood disorders 
(Allgulander & Lavori, 1991).  Most patients, however, do not seek help.  Only 
16 to 40% of anxiety patients seek appropriate treatment due to avoidance and 
misdiagnosis, resulting in reduced work productivity, unnecessary medical 
procedures, and poor medication management (Angst & Dobler-Mikola, 1985; 
Thompson, Burns, Bartko, Boyd, Taube, & Bourbon, 1988; Pollard, Henderson, 
Frank & Margolis, 1989).  So the actual cost (including direct and indirect) of 
anxiety disorders may be much higher than estimated. 
 The Good News.  Many studies have demonstrated the efficacy of 
cognitive behavior therapy (CBT) in treating anxiety disorders (Craske, 1999; 
Barlow, 1988; Marks, 1978).  For instance, in 10 controlled studies of cognitive-
behavioral therapy for specific phobias, an average of 76% of participants 
improved after only 4.8 hours of therapy (Arntz & Lavy, 1993; Hellstrom, 
Fellenius, & Öst, 1996; Hellstrom & Öst, 1995; Öst, 1996; Öst, Fellenius, & 
Sterner, 1991; Öst, Ferebee, & Furmark, 1997; Öst, Hellstrom, & Kaver, 1992; 
Öst et al., 1982; Öst, Salkovskis, & Hellstrom, 1991; Öst, Sterner, & Fellenius, 
1989).  This figure rose to 78% after 11 months and the attrition rate was only 
2%.   
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The Bad News. Unfortunately, not all patients respond to CBT (5-50%) 
and up to 20% of anxiety patients will relapse within 6 months of CBT cessation 
(Barlow, Gorman, Shear, & Woods, 2000).  Furthermore, as mentioned above, 
only 16 to 40% of anxiety patients seek appropriate treatment due to avoidance 
and misdiagnosis.  This may be due to practitioners and patients alike not being 
adequately educated regarding effective treatments.  In one study, 76% of 
claustrophobics who sought treatment reported that they would have sought 
treatment earlier if they had known effective non-pharmacological methods were 
available (Rachman, 1990).   
 Reasons for Non-Responders and Relapse (Safety Behaviors). Given 
these fluctuations in treatment response, it is important to understand the theories 
of fear reduction and the mechanisms involved in the maintenance of fear.  A 
comprehensive conceptualization of the factors involved in the maintenance of 
fear was suggested by Salkovskis and colleagues (1991).  Salkovskis’ suggested 
that safety behaviors, which can be any of a variety of behaviors (e.g. avoidance, 
escape, taking or carrying medication, cognitive distraction, sitting down to 
prevent fainting, or blending food to prevent choking) that are perceived as 
actively preventing a feared outcome, will prevent threat disconfirmation. Our 
pilot research suggests that safety behaviors do, in fact, exert a detrimental effect 
on fear reduction (see below).  At least four theories have been suggested that 
may explain why safety behaviors interfere with fear reduction: 1) diminished 
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cognitive resources (Sloan & Telch, 2001), 2) the threat transmission model 
(Sloan & Telch, 2001, and 3) context effects (Powers, Smits, & Otto, 2005), and 
4) misattribution of safety to the safety behavior (Salkovskis, 1991).  The current 
study is intended to rigorously test the misattribution theory of how safety-
behaviors exert their detrimental effects on fear reduction.   
 Attribution Theory and Combined Treatments Attribution theory 
describes how people explain events and the behavioral and emotional 
consequences of those explanations.  In his book The Psychology of Interpersonal 
Relationships, Fritz Heider referred to attribution theory as “naïve” psychology 
(Heider, 1958).  In two separate reviews of combined treatments for panic 
disorder/agoraphobia, Telch, Tearnan, and Taylor (1983) and Telch (1988) 
discussed the possibility that combining medications and Exposure may lead to an 
undermining of personal mastery due to external attribution effects.  More 
recently, attribution theory has been applied to the study of combined medication 
and CBT relapse (Basoglu, Marks, Kilic, & Brewin, 1994; D. Barlow, personal 
communication, March 6, 2003; Biondi, & Picardi, 2003; Marks, et al., 1993).  
Basoglu, Marks, Kilic, and Brewin (1994) investigated the role of attribution in 
predicting relapse in patients treated with medication (alprazolam or placebo) plus 
CBT (exposure or relaxation).  They found that attributions of improvement to the 
medication (alprazolam or placebo) predicted relapse.  However, they did not 
include an exposure only condition, nor did they control for specific instructions 
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describing the effects of the medication.  Barlow, Gorman, Shear, & Woods 
(2000) found that participants successfully treated with CBT + medication 
relapsed upon medication discontinuation. S. Raffa and D. Barlow (personal 
communication, March 6, 2003) suggested that misattribution of treatment gains 
to the medication may help explain the high relapse rate among participants in 
combination treatments.  Biondi and Picardi (2003) found that 60% of participants 
who made external/medication attributions in a combination treatment relapsed, 
whereas, no participants relapsed who made internal attributions (see figure). 
 
Biondi and Picardi (2003) 
Is it possible to manipulate attributions? Placebo + Instructional Set 
Manipulation Research. In a classic study, Storms and Nisbett (1970) 
administered pill-placebos to 42 insomniacs shortly before going to bed.  Some 
participants were told that the pills would cause arousal, while others were told to 
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expect sedation.  Consistent with their reverse placebo effect prediction, 
participants in the arousal condition experienced reduced sleep onset latency on 
the evenings that they ingested the “arousal” pills.  Storms and Nisbett (1970) 
hypothesized that this was because the participants had attributed their arousal to 
the pills rather than to their emotions.  However, these findings have not been 
replicated by others (Kellogg & Baron, 1975; Bootzin, Herman, & Nicassio, 
1976; Heffler, and Lisman, 1978).  In fact, these replication failures suggested a 
straightforward placebo effect.  Likewise, previous findings with exposure-based 
anxiety treatments demonstrate that the administration of a placebo prior to 
exposure treatment combined with bogus “stimulant” or “sedative” side effect 
profile descriptions, results in treatment outcome consistent with their 
instructional set (i.e. participants told that they are being given a stimulant 
experience less fear reduction whereas sedative instructions result in greater fear 
reduction) (Singerman, Borkovec, & Baron, R.S., 1976; Holroyd, 1978).  
Furthermore, removal of the placebo results in an effect opposite to the stimulant 
or sedative manipulations (i.e. return of fear in the sedative instruction group).  
This line of research was originally intended to produce a “reverse placebo” effect 
with anxiety patients.  However, consistent with the replication failures mentioned 
above, the research supports a straightforward placebo effect.  Therefore, this 
model may be applied to the study of treatment-relevant attributions.  
The previous research leads to four primary questions:  
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1) Do safety behaviors (such as taking medication) interfere with fear 
reduction? 
2) Does the reduction of the utilization of these behaviors increase the 
efficacy of CBT treatment? 
3) Do these behaviors interfere only when they are used? or do they even 
exert a detrimental effect when they are perceived as available (i.e. 
carrying medication but not taking it)? 
4) How do these behaviors exert their detrimental effects (i.e. 
distraction?, misattribution?, both?)? 
Research on the Detrimental Effects of Safety Behaviors on Fear 
Reduction.  Williams et al (1984) found safety behavior fading and guided 
mastery treatment in 32 intractable height and driving phobics resulted in 
significantly greater between trial fear reduction than the exposure only and 
control conditions.  However, safety behavior fading was not isolated in this 
study.  Wells (1995) treated 8 socially phobic patients in a counterbalanced 
within-subjects design.  Exposure combined with the fading of safety behaviors 
resulted in significantly more fear reduction than exposure alone.  Salkovskis 
(1991) suggested that safety behaviors should be faded during treatment to 
prevent patients from attributing safety to the safety behaviors themselves 
Salkovskis (1999) found significantly greater improvement in PDA patients who 
were encouraged to fade safety behaviors during exposure compared to those who 
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continued to use them. Sloan and Telch (2001) demonstrated that treatment 
outcome is compromised when safety behaviors are made available during 
exposure treatment. However, only about 50% of the participants actually made 
use of the available safety behaviors.  Therefore, in a follow-up study we 
randomized participants to actual use of safety behaviors versus perceived 
availability – no use and determined that they interfered equally with fear 
reduction (Powers, Smits, & Telch, 2004).  In addition, Telch, Smits, Powers, 
Sloan, Wolitzky, & Horowitz (2005) demonstrated that fading the use of safety 
behaviors following treatment results in more favorable outcome at follow-up. 
 The Current Study The question remains, how does medication taking 
exert a detrimental effect?  Misattribution theory may explain return of fear 
following successful combined CBT and medication treatment.  To test this 
hypothesis, the current study did not include an active medication and the 
attribution manipulation occurred after post-treatment ruling out a straight 
placebo effect during exposure - only leaving the possibility of misattribution by 
delivering the instructional set manipulation after the post-treatment and prior to 
the follow-up assessment. 
2.4 Hypotheses 
 We expected that:  
1. The Exposure-Pill placebo + Relaxation instruction group (EPR) would 
show reduced efficacy compared to the other exposure conditions. 
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2. The Exposure-Pill placebo + Arousal instruction group (EPA) would 
outperform all three active-treatment groups. 
3. All of the active-treatment groups would outperform the placebo treatment 
group.  The placebo group would outperform the wait-list condition. 
4. The reduced fear reduction in the EPR condition would be mediated by 
medication attributions. 
5. Based on previous studies from this laboratory, findings would not be 
moderated by age, gender, diagnostic status, or ethnicity. 
 
These data would suggest that elimination of medication facilitation attributions 
during medication withdrawal might lead to reduced relapse rates.  Therefore, an 
internal attribution rationale could be added to existing medication 
discontinuation manuals (Otto, Jones, Craske, & Barlow, 1996; Otto, Pollack, & 


































CHAPTER 3: METHOD 
3.1 Participants 
Participants (N=95) were claustrophobic college students from the 
University of Texas at Austin (n = 83) and severely claustrophobic participants 
from the community (n = 12). The college participants were selected from a large 
subject pool of approximately 5,000 introductory psychology students through a 
two stage screening procedure.  University of Texas students received partial 
course credit for their participation in the experiment.  The community sample 
was not reimbursed for participation. The final sample consisted primarily of 
women (71%), ranging in age from 18 to 60 years (M = 20.11; SD = 6.23). 
Marital status of the participants was 90% single, 8% married, and 2% divorced. 
Most participants (74%) met full Diagnostic and Statistical Manual of Mental 
Disorders (4th ed.; DSM-IV; American Psychiatric Association, 1994) criteria for 
claustrophobia, whereas 26% met all DSM-IV criteria with the exception of 
Criterion E (i.e., the person must experience significant interference in social, 
academic, or work functioning or experience marked distress about having the 
phobia). The ethnic breakdown of the sample was 70% Caucasian, 17% Mexican 
American, 1% African American, 1% Asian American, and 11% Indian 
American. This is similar to the ethnicity breakdown in previous studies from this 
laboratory (60% Caucasian, 14% Asian American, 12% Hispanic, 3% African 
American, 1% American Indian, 10% Other).  This closely matches the ethnic 
breakdown of the local community and the University of Texas at Austin. 
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Inclusion Criteria 
a) Marked claustrophobic fear, indicated by a subjective fear rating of 
moderate or higher and inability to remain in our claustrophobia test 
chamber for two minutes with a fear level greater than 50 on a 100-point 
scale; 
b) Between the ages of 18-65 
c) English Speaking 
Exclusion Criteria 
a) Current use of psychotropic medications 
b) Presence of a medical condition, which was assessed through the intake 
interview (i.e., pregnancy, seizure disorder, respiratory disorder, 
cardiovascular disease) that would contraindicate participation in one or 
more treatment or assessment activities.  
c) Currently receiving psychosocial treatment targeting claustrophobia. 
3.2 Experimental Design 
Participants were randomly assigned to one of six 30-minute exposure 
conditions: (a) Exposure-No Pill (ENP), (b) Exposure + Pill Placebo + Arousal 
Instruction (EPA), (c) Exposure + Pill Placebo + Relaxation Instruction (EPR), 
(d) Exposure + Pill Placebo + Neutral Instruction (EPN), (e) credible 
psychological placebo treatment (PLT), or (f) wait-list (WL). Outcome 
assessment consisted of self-report questionnaires and subjective and behavioral 
responses during two consecutive behavioral approach tests conducted at 
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pretreatment, post-treatment, and follow-up. Treatment process data consisted of 
subjective ratings of peak fear, suffocation, and entrapment concerns collected 
during each exposure trial (see below).  The primary dependent variables were 
self-reported peak fear during the behavioral assessments and the total score on 
the Claustrophobia Questionnaire (Rachman & Taylor, 1993). 
 Design Issues. 
1. Why include a no exposure credible placebo treatment? The inclusion of 
the no exposure placebo condition was important for several reasons. First, 
it provided a frame of reference for judging the specificity of the 30-min. 
self-guided exposure treatments. Second, it controlled for non-specific 
treatment effects. 
2. Why propose such a brief duration of exposure treatment? The in vivo 
exposure treatment described in this application has been used in six 
published treatment studies with claustrophobics. The pre to post effect 
sizes from these studies have been large ranging from 1.56 to 3.19. Further 
evidence of the potency of our brief treatment can be seen from our 
reports using categorical indices of treatment response developed by 
Jacobson and colleagues. Using a stringent criterion of treatment response, 
which includes both demonstration of statistically reliable change and 
clinically significant change at the level of the individual subject, 84 to 
100% of claustrophobics undergoing exposure-based treatment achieve 
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high end-state functioning at follow-up. It should also be noted that the 30 
min. duration is a bit misleading in that the actual treatment session takes 
approximately 90 min. Finally, other investigators (see review by Öst) 
have also demonstrated potent effects of one-session exposure treatments 
of specific phobias. 
3. Why include an exposure – no pill condition? By comparing the pre to 
post change for the three pill conditions versus the exposure- no pill 
condition, we were able to confidently rule out the possibility that the 
mere taking of a pill during exposure therapy affects level of improvement 
and subsequent return of fear at follow-up. 
4. Why include the exposure + pill with neutral expectation condition? This 
condition provided the most appropriate comparison group for testing the 
facilitation and interferencel attributional effects outlined in Study Aims 1 
& 2.
5. Why wait until after exposure therapy and the posttreatment assessment 
before applying the attribution manipulation? If the attribution 
manipulation were to take place prior to treatment, it would likely have 
resulted in straight placebo effect in the EPR condition (Shapiro & 
Shapiro 1997) and a nocebo effect in the EPA condition (Hahn, 1997; 
Benson, 1997).  This differential treatment response would then have 
made return of fear (ROF) comparisons at follow-up more difficult to 
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interpret. In other words, would posttreatment differences be due to 
attributions or placebo effects? Likewise, if the attributions were given 
prior to the posttreatment assessment participants would still believe the 
medication was onboard and thus a placebo or nocebo effect could interact 
with study hypotheses.  
6. Why include the waitlist condition?  This condition controlled for the 
effects of time and multiple assessments.   
3.3 Materials 
3.3.1 Pill Placebo 
Pill Placebo. The pill placebo consisted of one number 3-size capsule with 
250mg vitamin C that was prescribed by Alexander Bystritsky, M.D., Ph.D. who 
is a professor of psychiatry at the UCLA School of Medicine and Director of the 
UCLA Anxiety Disorders Program and UCLA Treatment Resistant OCD 
Program.  A single pill was provided to each participant in a clear plastic cup. 
3.3.2 Measures 
3.3.2.1 Diagnostic Interview 
World Health Organization Composite International Diagnostic Interview 
(CIDI). The CIDI is a fully structured interview that maps symptoms elicited 
during the interview onto Diagnostic and Statistical Manual of Mental Disorders-
IV (DSM-IV) diagnostic criteria and reports whether the diagnostic criteria are 
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satisfied.  Only the Specific Phobia module of this interview was administered to 
participants.  The CIDI has demonstrated excellent inter-rater reliability, adequate 
test-retest reliability, and good validity (Andrews, 1998). In addition, in the 
National Comorbidity Study – Replication Kessler et al. (2005) reported generally 
good concordance between the CIDI and SCID. However, with a poor positive 
predictive value (44%) and a high negative predictive value (90%) the CIDI may 
tend to over diagnose specific phobia (Kessler et al., 2005).  
3.3.2.2 Primary Outcome Measure 
Clinical Status. A categorical classification of clinically significant change 
(pre to post-treatment) was derived using the analytic strategy recommended by 
Jacobson & Truax (1991). This classification requires that a participant achieve a 
level of improvement from their pretreatment level that is both statistically 
reliable and clinically meaningful (i.e., post-treatment scores move into the 
normal range). Participants were classified as achieving clinically significant 
change at post-treatment if they met the following three conditions: (a) achieved 
terminal behavioral performance in the claustrophobia test chamber at 
posttreatment (i.e., was able to remain in the test chamber for the entire two min.; 
(b) the participant displayed a statistically reliable pre – to posttreatment 
reduction in reported fear during the claustrophobia challenge as measured by the 
Jacobson & Traux’s (1991) Reliable Change Index (RCI); and (c) the magnitude 
of fear reduction from pre to posttreatment was clinically meaningful as defined 
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by a pre – to posttreatment reduction in subjective fear of at least two standard 
deviations. 
3.3.2.3 Secondary Outcome Measures 
The Claustrophobia Questionnaire (CLQ). The Claustrophobia 
Questionnaire is a 26 item self-report scale for assessing claustrophobia severity 
and includes two subscales [Suffocation Scale (SS) & Restriction Scale (RS)].  
The CLQ has demonstrated good predictive and discriminant validity as well as 
good internal consistency and test-retest reliability (Radomsky, Rachman, 
Thordarson, McIsaac, & Teachman, 2001).  The suffocation scale (SS) is a 14-
item self-report scale for assessing fear of suffocation.  Items (e.g. “Working 
under a car for 15 minutes.”) are rated on a 0 (not at all anxious to 4 (extremely 
anxious) Likert scale.  The scale has shown good psychometric properties 
(Rachman & Taylor, 1993).  The Restriction Scale (RS) is a 12-item self-report 
scale for assessing entrapment fears.  Items (e.g., standing for 15 minutes in a 
straight jacket) are rated on 0 (not at all anxious) to 4 (extremely anxious) Likert 
scale.  The scale has shown good psychometric properties (Rachman & Taylor, 
1993). 
Peak Fear. Immediately upon exiting the BAT chamber, participants rated 
their peak fear while in the chamber. Fear level was measured on a Likert scale 
ranging from 0 (No fear) to 100 (Very Severe Fear). These data were collected at 
the two pre-treatment BATs, post-treatment BAT, and the two follow-up BATs. 
44
Beck Anxiety Inventory (BAI). The BAI is used for the assessment of 
general levels of anxiety and helped determine if randomization was successful.  
Each item is scored (0-3) and summed. A score of 10+ is typically considered to 
indicate clinically significant levels of anxiety. Relevant levels of anxiety: 10-14 
Borderline 15-20 Mild 21-30 Moderate 31-40 Severe 41+ Profound.  The BAI is 
internally consistent (alpha=.94), with adequate test-retest reliability (,75 for I 
week, and.67 for 2 weeks) (Beck, Epstein, Brown, & Steer, 1988; Fydrich, 
Dowdall, & Chambliss, 1992). 
Claustrophobic Behavior Questionnaire (CBQ). The Claustrophobic 
Behavior Questionnaire is a 20-item author constructed questionnaire to assess the 
number of times participants actually engaged in behaviors inconsistent with 
claustrophobia over the previous week such as riding in an elevator.  
Claustrophobic Concerns Questionnaire (CCQ). The CCQ (Valentiner, 
Telch, Petruzzi, & Bolte, 1996) is an empirically derived two-factor scale 
assessing danger expectancies associated with claustrophobia.  Items (e.g., I might 
be trapped, I might run out of air) are rated on a Likert scale ranging from 0 (no 
concern) to 100 (extreme concern).  Each of the two sub-scales (entrapment and 
suffocation) has high internal consistency and test-retest reliability.  In a previous 
study the entrapment and suffocation scales showed internal consistency 
coefficients of 0.93 and 0.91 respectively (Valentiner, Telch, Petruzzi, & Bolte, 
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1996).  The CCQ will be administered at the end of each treatment trial in order to 
assess changes in threat expectancies over the course of treatment. 
3.3.2.5 Manipulation Check 
Credibility Assessment [Credibility Expectancy Questionnaire (CEQ)] 
Prior to beginning treatment, but after completing pre-treatment BAT 1, pre-
treatment BAT 2, and treatment description, all participants completed the 
Credibility/Expectancy Questionnaire (CEQ by Devilly & Borkovec, 2000).  This 
scale is widely used for assessing treatment expectancy and rationale credibility in 
clinical outcome studies. The scale has demonstrated: factors that are stable across 
multiple populations, high internal consistency, and good test-retest reliability 
(Devilly & Borkovec, 2000). 
Treatment Gain and Attribution Questionnaire (TGAQ). The Treatment 
Gain and Attribution Questionnaire was created by the authors and consists of 
three items that asses: 1) the participant’s subjective rating of overall 
improvement, 2) to what extent the participant felt that the medication made the 
exposures easier, and 3) to what extent the participant felt that the medication 
made their exposures more difficult.  The scores represent the measurement of 




A two-step process was used to select participants who contacted the 
laboratory or who were identified through the introductory psychology classes. 
First, potential participants were identified by their responses to two screening 
questions asking respondents to rate on a Likert scale their fear of enclosed places 
in general and their fear of entering and remaining in a dark chamber for several 
minutes.  Respondents reporting moderate or severe fear to both items were 
invited for further testing. During this session, participants were administered a 
diagnostic interview [World Health Organization Composite International 
Diagnostic Interview (CIDI), a more detailed claustrophobia history 
questionnaire, and several paper-and-pencil measures.  After completing these, 
two consecutive behavioral approach tests (BAT 1 & 2) were administered.  
Participants who were able to complete either of the two BATs with a SUDS 
rating of less than 50 on a 100-point scale, were deemed insufficiently phobic and 
excluded. 
3.4.2 Behavioral Approach Tests (BAT-1) 
Upon completing informed consent procedures, and several self-report 
questionnaires (see below), participants were asked to look inside the BAT-1 
chamber for five seconds. The chamber consists of a 72”long by 36” by 24” box 
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that is not airtight.  After viewing the inside of the chamber for five seconds, 
participants completed a pre-exposure questionnaire assessing the participant’s 
anticipated fear, performance, and likelihood of panic. Each of these phobic 
appraisal dimensions was assessed using Likert scales. They were then provided 
the following instructions: “I am now going to open the door of the chamber. You 
are to get inside and remain there for as long as you can. I will signal to you when 
the trial is over by opening the door. It is important that you understand that you 
can leave the chamber at any time if you get too uncomfortable. The door of the 
chamber will remain unlocked at all times in the event that you want to come out. 
Do you have any questions?"  Length of time in the chamber was monitored. 
Maximum time spent in the chamber was limited to 2 minutes, though 
participants were not made aware of the two-minute limit. After 2-min., the 
experimenter opened the door and instructed the participant to exit. Upon exiting, 
the participant completed ratings of peak fear. 
3.4.3 Generalization Behavioral Approach Tests (BAT-2) 
Upon completing BAT-1 participants were asked to look inside the BAT-2 
chamber for five seconds. BAT-2 is a similar box to BAT-1 but is upright and the 
participant stands inside during the assessment.  The rest of the BAT-2 procedure 
is identical to BAT-1.  
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3.4.4 Treatment Conditions 
Procedures Common to All Treatment Conditions. Eligible participants 
returned one week later to begin treatment. Participants in each of the four active 
treatment conditions received a total of 30 min. of self-guided in vivo exposure to 
the same claustrophobia chamber used to conduct the pretreatment BAT 1. All 
treatment instructions were delivered by digital video recording to insure 
consistency and reduce error variance. At the beginning of the treatment session, 
participants in the three instructional set manipulation conditions were 
administered a placebo pill (one 250 milligram vitamin C tablet as described by: 
Holroyd, 1978) and told that the experiment would be investigating anxiety 
treatment while simultaneously examining the effect of “Adomoxin” (a made up 
name of an herbal supplement) on memory.  Next, participants were provided 
instructions similar to those given during the baseline assessment with additional 
instructions specific to their treatment condition. A general treatment rationale 
was provided emphasizing the fear-reducing effects of direct confrontation with 
the feared situation. Additional treatment rationales specific to treatment 
condition were also provided following the treatment (see below). For each trial, 
participants were instructed to enter the chamber and remain inside for as long as 
possible up to a maximum of five min.  Participants were also informed that they 
were free to exit the chamber at any time if they become too uncomfortable.  
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Prior to the start of each treatment trial, participants completed ratings of 
anticipated fear, panic likelihood, danger, and self-efficacy for the upcoming trial.  
Upon exiting the chamber, participants completed ratings of fear, panic, and 
anxiety symptom severity.   The interval between treatment trials was 
approximately five min. The duration of each trial was recorded by the 
experimenter along with a running total of exposure duration.  Treatment 
proceeded in this fashion until each participant’s total duration of exposure 
reached 30-min.  This resulted in equivalent durations of exposure for all 
participants.  The instructional set manipulation occurred following the 30-min. of 
exposure and post-treatment assessment. 
Exposure Only-No Pill (EO) Participants in the Exposure-No Pill group 
received the treatment as mentioned above without administration of the pill 
placebo. They viewed a digital video with the following script, “Hello, I’m Mark 
Powers and I will be introducing the treatment phase of this study to you.  I would 
like to first thank you for agreeing to participate in our study on claustrophobia.  
Claustrophobia, as you may know, is a fear of enclosed spaces.  This study is one 
in a series of five projects we have recently conducted to maximize the efficacy of 
our already potent treatments for phobias.  This study is designed to better 
understand how confronting one’s fear leads to reductions in phobias. We know 
that fear responses like yours are fueled by avoidance of enclosed spaces and 
specific beliefs of harm connected to being in the enclosed space.   For example, 
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some people are afraid that they will not get enough air, others are afraid that they 
will be trapped in the enclosed space, and some people report both concerns.   
One effective strategy for reducing these fears is to be exposed to the feared 
situation repeatedly until the anxiety decreases.  We call this treatment strategy 
in-vivo exposure.  The experimenter will soon open the door of the chamber. You 
are to get inside and lie down on the sanitary paper with your head on the pillow, 
and remain there as long as you can. It is important that during the entire exposure 
that you focus on the belief that you may not get enough air and that you may be 
trapped in the enclosed space.  The experimenter will signal to you when the trial 
is over by opening the door. Do know that you can leave the chamber at any time 
if you get too uncomfortable; however, I would like you to try and stay for at least 
five minutes .The door of the chamber will remain unlocked at all times. In the 
event that you need to leave the chamber before the five minutes are over, simply 
push the doors open and exit the chamber.  After you exit the chamber, you will 
answer more questions and we will repeat the process.” 
Exposure + Pill Conditions (EPN, EPA, EPR). Participants in the 
Exposure + Pill groups received the treatment as mentioned above with 
administration of the pill placebo. They viewed a digital video with the following 
script, “Hello, I’m Mark Powers and I will be introducing the treatment phase of 
this study to you.  I would like to first thank you for agreeing to participate in our 
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study on claustrophobia.  Claustrophobia, as you may know, is a fear of enclosed 
spaces.  This study is one in a series of five projects we have recently conducted 
to maximize the efficacy of our already potent treatments for phobias.  This study 
is designed to better understand how confronting one’s fear leads to reductions in 
phobias. We know that fear responses like yours are fueled by avoidance of 
enclosed spaces and specific beliefs of harm connected to being in the enclosed 
space.   For example, some people are afraid that they will not get enough air, 
others are afraid that they will be trapped in the enclosed space, and some people 
report both concerns.   One effective strategy for reducing these fears is to be 
exposed to the feared situation repeatedly until the anxiety decreases.  We call this 
treatment strategy in-vivo exposure. In addition, neuropsychiatric research has 
demonstrated the important role of the limbic system in mediating the fear 
response between the cortex and the brain stem.  The limbic system includes the 
amygdala, the septum, the cingulate, and the hippocampus.  In particular, the 
hippocampus is associated with the encoding of fear and other emotional 
memories.  Studies have demonstrated the importance of memory in successful 
anxiety treatment protocols.  In addition, it has been suggested that adomoxin 
(an herbal supplement) may be related to enhanced memory consolidation.  
Therefore, we will also be administering either a pill-placebo or a 10mg 
capsule of adomoxin prior to your exposure sessions. Please take the pill in 
front of you now with the provided cup of water. The experimenter will soon 
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open the door of the chamber. You are to get inside and lie down on the sanitary 
paper with your head on the pillow, and remain there as long as you can. It is 
important that during the entire exposure that you focus on the belief that you may 
not get enough air and that you may be trapped in the enclosed space.  The 
experimenter will signal to you when the trial is over by opening the door. Do 
know that you can leave the chamber at any time if you get too uncomfortable; 
however, I would like you to try and stay for at least five minutes .The door of the 
chamber will remain unlocked at all times. In the event that you need to leave the 
chamber before the five minutes are over, simply push the doors open and exit the 
chamber.  After you exit the chamber, you will answer more questions and we 
will repeat the process.” 
Exposure + Pill Placebo + Arousal Instructional Set (EPA) Participants 
assigned to the arousal instructional set group were told that they received 
adomoxin which has an anxiogenic side effect profile that should have made the 
exposures much more difficult to determine the effects of arousal during 
exposure. They viewed a digital video with the following script, “First, I would 
like to thank you for participating in the treatment phase of this experiment.  It is 
important that you know, however, the capsule that you ingested contained 10 
mg of adomoxin and is associated with stimulating autonomic nervous 
system activation and a mild side-effect profile including: anxiety, tremors, 
shakiness, breathlessness, and sweating.  Because of its stimulant-like side 
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effects, undergoing the exposures under the influence of adomoxin should 
have made the exposures much more difficult. Do know that adomoxin has a 
short half-life (or is quick acting), thus all behavioral and physiological effects 
should disappear within the next hour. A major aim of the study was to observe 
the stimulating effects of this medication on people’s reactions to exposure-based 
treatment. We expect that the stimulating nature of adomoxin made your fear 
level while in the chamber much higher than it would have been without the 
medication. However, it was important that you and your experimenter be 
blinded to the stimulating or anxiety producing side-effect profile to rule out 
expectancy effects. Consequently you were not told of the stimulating or anxiety 
producing side-effects until after your exposures. Please remember that you will 
need to return in one-week for a follow-up visit, which you may schedule with 
your experimenter now.  At this follow-up visit, you will not receive any 
medication.  At the conclusion of the study, you may request through email 
information on the final results of the study. Please don’t hesitate to ask your 
experimenter or Mark Powers if you have further questions. Thanks again for 
your participation.” 
Exposure + Pill Placebo + Neutral Instructional Set (EPN) Participants 
assigned to the neutral instructional set group were told that they were 
administered a placebo with a neutral side effect profile that should not have had 
any effect on their exposures.  They viewed a digital video with the following 
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script, “First, I would like to thank you for participating in the treatment phase of 
this experiment.  It is important that you know, however, the capsule that you 
ingested was not adomoxin, but rather a pill placebo. In case you don’t know, 
a placebo is an inactive substance that is commonly used in medication studies to 
control for expectancy effects – sometimes referred to as the placebo effect. 
Because placebos have no active effects on the autonomic nervous system, your 
ingestion of the pill placebo should have had no significant effect on your 
reactions while in the chamber. However, having you take the pill placebo 
allowed us to control for the effects of expectancy and thus provided an important 
comparison with other subjects who received active medication. A major aim of 
the study was to observe the effects of medication on people’s reactions to 
exposure-based treatment. However, it was important that you and your 
experimenter be blinded to the true identity of the substance to rule out 
expectancy effects. Consequently you were not told that you were actually 
receiving a placebo until after your exposures. Please remember that you will 
need to return in one-week for a follow-up visit, which you may schedule with 
your experimenter now.  At this follow-up visit, you will not receive any 
medication. At the conclusion of the study, you may request through email 
information on the final results of the study. Please don’t hesitate to ask your 
experimenter or Mark Powers if you have further questions. Thanks again for 
your participation. “ 
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Exposure + Pill Placebo + Relaxation Instructional Set (EPR) 
Participants assigned to the relaxation instructional set group were told that they 
received adomoxin with an anxiolytic side effect profile that should have made 
the exposures much easier to determine the effects of sedation/relaxation during 
exposure.  They viewed a digital video with the following script, “I would like to 
thank you for participating in the treatment phase of this experiment.  It is 
important that you know, however, the capsule that you ingested contained 
10mg of adomoxin and is associated with inhibiting  autonomic nervous 
system activation and has a mild side-effect profile including: sedation, 
relaxation, and sleepiness.  Because of its tranquilizing effects, undergoing 
the exposures under the influence of adomoxin should have made the 
exposures much less difficult.  Do know that adomoxin has a short half-life (is 
quick acting), thus all behavioral and physiological effects should disappear 
within the next hour. A major aim of the study was to observe the effects of this 
medication on people’s reactions to exposure-based treatment. We expect that 
the sedating nature of adomoxin made your fear level while in the chamber 
much lower than it would have been without the medication.  However, it was 
important that you and your experimenter be blinded to the sedating or anxiety 
reducing side-effect profile to rule out expectancy effects. Consequently you were 
not told of the sedating or anxiety reducing side-effects until after your exposures. 
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Please remember that you will need to return in one-week for a follow-up visit, 
which you may schedule with your experimenter now.  At this follow-up visit, 
you will not receive any medication. At the conclusion of the study, you may 
request through email information on the final results of the study. Please don’t 
hesitate to ask your experimenter or Mark Powers if you have further questions. 
Thanks again for your participation. “ 
Credible Psychological Placebo Treatment (PLT) Participants randomized 
to this condition received a similar rationale emphasizing their fear is fueled by 
avoidance and specific concerns, along with instructions emphasizing the 
beneficial effects of relaxation. Participants received the following specific 
instructions: “Hello, I’m Mark Powers and I will be introducing the treatment 
phase of this study to you.  I would like to first thank you for agreeing to 
participate in our study on claustrophobia.  Claustrophobia, as you may know, is a 
fear of enclosed spaces.  This study is one in a series of five projects we have 
recently conducted to maximize the efficacy of our already potent treatments for 
phobias.  This study is designed to better understand how confronting one’s fear 
leads to reductions in phobias. We know that fear responses like yours are fueled 
by avoidance of enclosed spaces and specific beliefs of harm connected to being 
in the enclosed space.   For example, some people are afraid that they will not get 
enough air, others are afraid that they will be trapped in the enclosed space, and 
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some people report both concerns.   One effective strategy for reducing these fears 
is to be exposed to the feared situation repeatedly until the anxiety decreases.  We 
call this treatment strategy in-vivo exposure. However, prior to your second 
chamber exposure, we are going to enhance your fear reduction process by 
inducing heightened beta wave brain activity with a device called the Digital 
Audio Visual Integration Device or DAVID. Beta waves are high frequency, 
low amplitude brain waves seen while people are awake and relaxed immediately 
prior to the alpha wave activity of Stage 1 of sleep.  The DAVID induces these 
brain waves by delivering pulsed audio and visual stimuli.  These goggles will 
deliver flashing lights at 12Hz (cycles per second) and these headphones will 
deliver audible ticks (like a metronome) also at 12Hz (cycles per second) to 
induce the beta wave relaxation.    Prior research has shown that the delivery of 
pulsed audio and visual stimuli is an effective strategy for enhancing beta wave 
activity associated with relaxation.  The enhanced relaxation brought on by the 
beta wave activity will allow you to feel less anxious in the chamber. After this 
video, the experimenter will have you recline in the chair and we will then turn on 
the device.  You will put on the goggles and headphones and keep your eyes 
closed during the DAVID exposure.  It is important that throughout the entire 5-
minute exposure that you focus on the pulsing lights and sounds. If your mind 
starts to wander, simply return your focus to the pulsing lights and sounds.  After 
turning off the lights, the experimenter will leave the room for five minutes while 
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you relax.  The door to the room will remain unlocked at all times and you may 
leave at any time.  When the experimenter returns, you will answer more 
questions and we will repeat the process. “ 
The Digital Audio Visual Integration Device (DAVID) developed by 
Comptronic Devices (9876-A 33rd Ave., Edmonton, AB) is used by health care 
professionals as a relaxation device. It is a small soundboard about the size of a 
stereo receiver, which includes a headset and plastic mask. The headset emits 
controllable ticking sounds, similar to those made by a metronome. The plastic 
mask resembles ski goggles, and delivers pulsed orange lights at controllable 
rates. In this study, the audio and video stimulus frequency was set at 12 Hz 
(cycles per second), which is higher than the rate at which the device is suggested 
to maximally produce relaxation and meditative states. This was done to assure 
that any relaxing properties of the DAVID would be due to a placebo effect. 
Following the rationale, participants completed the credibility/expectancy 
questionnaire (CEQ; Devilly & Borkovec, 2000).  We have used the DAVID in 
several published studies (i.e. Powers, Smits, & Telch, 2004). Credibility 
assessment in our previous study showed that claustrophobics perceived the 
DAVID to be as credible as exposure therapy (Powers, Smits, & Telch, 2003; 
Leonard, Telch, & Harrington, 1999).  
Wait-List (WL).  This group was informed that they were placed on a wait-
list. They returned for assessment one week later and again one week after that to 
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complete the post- and follow-up assessments.  Following the follow-up 
assessment, they were offered exposure treatment. 
3.4.5 Post-Treatment Behavioral Approach Test 
Following the treatment session and instructional set manipulation, 
participants completed another behavioral approach test identical to the pre-
treatment BATs.  Next, participants were asked to fill out the Treatment Gain and 
Attribution Questionnaire (TGAQ). 
3.4.6 Follow-up Behavioral Approach Test 
Participants returned after one-week to assess effects of the attribution 
manipulation and to complete the Follow-up BATs, which were identical to the 
previous two BATs. 
3.4.7 Debriefing  
Participants were made aware that some of them may have received a 
placebo treatment and that some groups may receive inaccurate information 
regarding the treatment.  This debriefing process took place at the conclusion of 
the follow-up assessment.  Debriefing included two components. One was a 
debriefing protocol; the other was an accompanying written debriefing statement. 
The debriefing protocol constituted a guideline for in-person interaction between 
participants and the investigator. It indicated: (a) how to review and explain the 
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nature of, and reasons for, the deception with the participants, (b) to express regret 
for the necessity of deceiving the participants, and  (c) to offer the participants a 
chance to ask questions or work through any confusion they might have. The 
written debriefing statement presented the same information in summary form, 
and included a contact telephone number and name for participants to call if they 
should have further questions or concerns.  The written debriefing statement: (a) 
expressed regret for the necessity of deceiving the participants, (b) explained what 
the deception was and why it was necessary, (c) offered the subjects a chance to 
ask questions or work through any confusion they might have, and (d) offered 
information about sources of further support, counseling, or other assistance 
participants may desire as a result of the deception. It also introduced the 
participants to the broader conceptual and research issues involved. It was 
possible that a small number of participants may still experience some distress 
resulting from the study deception even after debriefing.  Dr. Telch was available 
for further debriefing and/or clinical management if necessary.  Participants were 
also asked if they still would like their data included in the analysis now that they 
were made aware of the deception. 
 
3.4.8 Manipulation Check  
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Participants were asked to rate: (a) prior to treatment, how credible did 
they feel their treatment condition sounded and how much they felt it would help 
reduce their fear (Credibility and Expectancy Questionnaire) and  (b) following 
treatment, to rate the level of overall improvement in their fear and how much of 
that improvement did they attribute to either medication, the psychosocial 
treatment, or both (Treatment Gain Attribution Questionnaire). To check on the
integrity of the instructional set manipulation (i.e., instructional manipulation
induced differential attributions of treatment gains), the author-constructed
questionnaire (TGAQ) was administered just after the posttreatment assessment
and prior to the follow-up assessment. Significantly greater medication facilitation
scores among the sedation condition relative to the neutral condition; and
significantly greater medication interference scores among those in the stimulant
condition relative to the neutral condition would provide evidence supporting the
success of our attribution manipulation.
See Figure for Flow Chart of Study Design. 
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3.4.9 Flow Chart of Study Design 
WL=Wait List 
PLT=Placebo Treatment 
EPR=Exposure+Pill Placebo+Relaxation Instruction 
EO=Exposure Only-No Pill 
EPN=Exposure+Pill Placebo+Neutral Instruction 
EPA=Exposure+Pill Placebo+Arousal Instruction 
 
Posttreatment Assessment, then Attributions a










a BAT-1 & BAT-2
WL
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CHAPTER 4: STATISTICAL ANALYSES 
4.1. Manipulation Checks 
To confirm that the randomization procedure resulted in equivalent 
experimental groups, we examined group differences in pre-treatment levels of all 
dependent measures using one-way ANOVAs.  Because the experimental 
manipulation did not occur until after all groups received treatment and 
posttreatment assessment, we expected the three exposure conditions would show 
equivalent levels of pre to posttreatment improvement and that this improvement 
would be significantly greater than the improvement observed in the no-exposure 
placebo condition. The equivalence of pre to posttreatment improvement among 
the three exposure conditions was tested using one-way ANOVAs. A series of a 
priori contrasts comparing the three exposure conditions to the placebo condition 
were performed for each continuous dependent measure separately as a check on 
the integrity of the exposure implementation. To check on the integrity of the 
instructional set manipulation (i.e., instructional manipulation induced differential 
attributions of treatment gains), an author-constructed questionnaire (TGAQ) was 
administered after the posttreatment assessment and prior to the follow-up 
assessment. Significantly greater medication facilitation scores among the 
sedation condition relative to the neutral condition; and significantly greater 
medication interference scores among those in the stimulant condition relative to 
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the neutral condition would provide evidence supporting the success of our 
attribution manipulation. 
4.2. Primary Outcome Analyses 
Chi Square analyses were used to test the hypothesis that participants 
randomized to the exposure plus sedation pill condition would display 
significantly poorer outcome at follow-up relative to the exposure plus neutral pill 
condition. The primary outcome variable was the percentage of participants 
achieving significant improvement on peak fear during the behavioral test at 
follow-up using the reliable change index of Jacobson and colleagues. A similar 
analysis was performed to test the hypothesis that those randomized to the 
exposure plus stimulant pill condition would show significantly greater 
improvement than those in the exposure plus neutral pill condition. 
4.3. Secondary Outcome Analyses 
Secondary Outcome Analyses. (i.e. CLQ and CBQ) were conducted using 
repeated measures ANOVAs. Separate analyses were conducted for Pre- to 
Posttreatment and for Post- to Follow-up. The Pre- to Posttreatment analyses 
suggested the effects of treatment. The Post- to Follow-up analyses suggested the 
unique contribution of the attribution manipulation to test the hypotheses that 
misattribution would result in reduced treatment response in the sedation group, 
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equivalent response in the neutral group, and a potentiated response in the 
stimulant group. 
4.4. Moderator Analyses 
The potential treatment moderating effects of prerandomized individual 
factors such as age, ethnicity, gender, marital status, source (community vs. 
students), and diagnostic status were examined using the analytic strategy for 
testing moderation recently proposed by Kraemer, Wilson, Fairburn, and Agras 
(2002). More specifically, residualized change scores from post to follow-up of 
the continuous outcome variables were subjected to a multivariate analysis of 
variance in which condition was entered as a between-groups factor while 
controlling for pre to post residualized change scores. Separate analyses were 
conducted for each of the potential moderators. In addition residualized change 
scores of the continuous outcome variables were subjected to a multivariate 
analysis of variance in which medication attribution (EPR vs. EPN) was entered 
as a between-groups factor. Separate analyses were conducted for each of the 
potential moderators. Moderator status was assigned to those factors that yielded 
significant interactions with the medication attribution factor. 
4.5. Mediation Analyses 
Mediation analyses as outlined by Baron and Kenny (1986) were 
performed to test the hypothesis that the differential treatment effects were 
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mediated by differential attributions as assessed by the TGAQ. In Step 1 we tested 
the effects of treatment on the proposed mediator by performing an ANOVA with 
treatment group (EPR vs. EPN) as the grouping factor and medication attributions 
(TGAQ) as the dependent variable. In Step 2 we tested the effect of treatment on 
outcome by performing an ANOVA with treatment group (EPR vs. EPN) as the 
grouping factor and post to follow-up residualized change scores (while 
controlling for pre to post residualized change scores) of the primary outcome 
measure as the dependent variable. In Step 3 we tested the relationship between 
the proposed mediator and outcome by regressing residualized change scores of 
the primary outcome measure on medication attributions. Finally, in Step 4 we 
tested the effect of treatment after controlling for medication attributions by 
entering the residualized change scores of peak fear from post to follow-up during 
BAT 1 as the DV, EPR vs. EPN as the grouping factor (while controlling for pre 
to post residualized change scores), and the scores from the Treatment Gain 
Attribution Questionnaire (Medication) as a covariate. Evidence that the 
differential treatment response observed at follow-up were no longer significant 
once controlling for attributions of treatment gains would provide support for the 
major study hypothesis. 
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CHAPTER 5: RESULTS 
5.1. Baseline Equivalence of Groups 
Differences between groups on continuous measures were examined at 
baseline using one-way ANOVAs to verify that random assignments of 
participants had produced comparable groups. Categorical variables were also 
compared at baseline with chi square analyses. An alpha level of 0.20 was 
selected as the cutoff to avoid overly conservative rejection of between-group 
differences at pretreatment. Variables included in these analyses were: 1) Age, 2) 
Beck Anxiety Inventory, 3) Claustrophobia Behavior Questionnaire, 4) 
Claustrophobic Concerns Questionnaire, 5) Claustrophobia Questionnaire, 6) 
Peak Fear during BAT1, 7) Duration of BAT1, 8) Peak Fear during BAT2, 9) 
Duration of BAT2.  No significant differences between groups at baseline were 
identified on any of these measures. In addition, the mean credibility and expected 
level of improvement, according to the Credibility and Expentacy Questionnaire 
(Devilly & Borkovec, 2000) was comparable across the exposure and placebo 
conditions (p>0.5).  
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5.2. Manipulation Check 
Attributions were assessed with the Treatment Gain Attribution 
Questionnaire (see Table 2). Consistent with prediction, the Exposure-Pill placebo 
+ Arousal instruction group (EPA) rated the interfering effects of the medication 
higher than the Exposure-Pill placebo + Neutral instruction group (EPN) [F(1, 36) 
= 610.50, p<.001]. Ratings of overall improvement, positive attributions about the 
treatment, and attributions about the helpful effects of the medication were not 
significantly different between these two groups. Also consistent with prediction, 
the Exposure-Pill placebo + Relaxation instruction group (EPR) rated the 
medication significantly more helpful than the Exposure-Pill placebo + Neutral 
instruction group (EPN) group as measured by the Treatment Gain Attribution 
Questionnaire – Medication, F(1, 28) = 159.72, p<.001, and the Instructional Set 
Manipulation Check questionnaire, F(1, 32) = 52.15, p<.001. In addition, the EPR 
group rated the harmful effects of the medication significantly lower than the EPN 
group, F(1, 33) = 7.11, p<.05. Ratings of overall improvement and positive 
attributions about the treatment were not significantly different between these two 































5.3 Treatment Outcome 
5.3.1 Effects at Posttreatment 
5.3.1.1 Posttreatment Within-Group Effects 
The waitlist condition did not show significant improvement on any of the 
outcome measures from pre- to posttreatment. As shown in Figure 1, the most 
consistent finding across groups was significant pre- to posttreatment 
improvement observed among all five treatment conditions (EO, EPA, EPN, EPR, 
& PLT) for peak fear in BAT 1 (all ps<.05).  In addition, the EO condition 
showed significant improvement in BAT 2 peak fear, the CLQ Suffocation Scale, 
the CLQ Total, and the Claustrophobic Behaviors Questionnaire (all ps<.05). The 
EPA group showed significant improvement on BAT 2 peak fear (p<.05). The 
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EPN condition showed significant improvement on BAT 2 peak fear, the CLQ 
Restriction Scale, the CLQ Total, and the Claustrophobic Behaviors 
Questionnaire (all ps<.05). The EPR group showed significant improvement on 
BAT 2 peak fear, the CLQ Suffocation Scale, the CLQ Restriction Scale, and the 
CLQ Total (all ps<.05). The PLT groups showed significant improvement on 



























5.3.1.2 Posttreatment Between-Group Effects 
The pattern of between-group differences for each of the a priori contrasts 
varied as a function of the specific outcome measure. Between-group effect sizes 
appear in Table 1. With regards to BAT 1 peak fear, the placebo group 
outperformed the waitlist group, F(1, 23)  = 12.44, p<.05. The contrasts testing 
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the exposure groups versus PLT, EO versus EPN, EPR versus EPN, and EPA 
versus EPN were not significant. There were no significant differences in 
suffocation fear, restriction fear, total score on the claustrophobia scale (CLQ), or 
on the Claustrophobic Behaviors Questionnaire. Finally, reductions in peak fear 
during BAT 2 were significantly greater among participants in the placebo group 
compared to the waitlist group, F(1, 23)  = 6.37, p<.05. No significant differences 
were observed between the exposure groups and PLT, EO and EPN, EPR and 
EPN, and EPA versus EPN. 
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Measures PLT vs. WL Treatment vs. PLT EO vs. EPN EPR vs. EPN EPA vs. EPN
Pre-Post Post-FU Pre-Post Post-FU Pre-Post Post-FU Pre-Post Post-FU Pre-Post Post-FU
BAT1 Peak fear .35 .18 .03 .07 .00 .01 .00 .13 .01 .01
BAT2 Peak fear .22 .07 .00 .03 .00 .00 .01 .07 .02 .00
CLQ: Suffocation .00 .00 .01 .02 .03 .06 .00 .02 .03 .01
CLQ: Restriction .08 .05 .01 .00 .04 .01 .01 .01 .01 .00
CLQ: Total .11 .08 .01 .00 .07 .04 .00 .01 .02 .01
CBQ .23 .15 .01 .02 .00 .01 .21 .17 .08 .07
Table 1.
Between group effect sizes (partial eta squared a) for post-treatment and follow-up fear indices.
Small=.01, Medium=.06, Large=.14, Cohen (1977)
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Table 2.
Means and standard deviations for post-treatment and follow-up fear indices.
Measures _ Exposure Only__ __ EPA __ ___ EPR ___ ______EPN______ Placebo __ Waitlist __
Pre Post FU Pre Post FU Pre Post FU Pre Post FU Pre Post FU Pre Post FU












































































































































































































































5.3.1.3 Posttreatment Clinical Significance 
Figure 1 presents data on clinically significant improvement rates at 
posttreatment for each of the six conditions. The percentage of participants 
achieving clinically significant improvement was 73%, 75%, 78%, 77%, 60%, 
and 10% for the EO, EPA, EPN, EPR, PLT, and WL groups, respectively. 
Significant differences were observed between PLT and WL, χ2(1, N = 25) = 
6.25, p < .05. No significant differences were observed between the exposure 
conditions and the PLT group, between the EPN and EO groups, between the 
EPR and EPN groups, or between the EPA and EPN groups. 
Figure 1: Post clinically significant improvement rates
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5.3.2 Effects at Follow-Up 
5.3.2.1 Follow-Up Within-Group Effects 
At follow-up the placebo group did not change significantly on any of the 
primary outcome measures. The waitlist condition showed no significant 
deterioration and showed further significant improvement on peak fear during 
BAT 2 (p<.05). The EPR group showed significantly increased peak fear during 
BAT 1 (p<.05).  The EO group maintained treatment gains and further improved 
on the CLQ Suffocation Scale (p<.05). The EPA group maintained gains and 
further improved on peak fear during BAT 2, the CLQ Suffocation Scale, the 
CLQ Restriction Scale, and the CLQ Total. The EPN condition maintained gains 
and further improved on peak fear during BAT 2, the CLQ Restriction Scale, the 
CLQ Total, and the Claustrophobic Behaviors Questionnaire (all ps<.05).  
5.3.2.2 Follow-Up Between-Group Effects 
On peak fear during BAT 1, participants in the placebo group 
outperformed the waitlist group, F(1, 23)  = 5.06, p<.05, the exposure groups 
outperformed the placebo group, F(1, 83)  = 6.08, p<.05, and the EPR group 
showed significantly increased fear compared to the EPN group, F(1, 33)  = 4.73, 
p<.05 . No other significant differences from posttreatment to follow-up up were 
observed.  
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5.3.2.3 Follow-Up Clinical Significance 
Figure 2 presents the data on the percentage of participants in each of the 
five treatment conditions who achieved clinically significant improvement at 
follow-up. The percentage of participants achieving clinically significant 
improvement was 87%, 85%, 89%, 53%, 40%, and 30% for the EO, EPA, EPN, 
EPR, PLT, and WL groups, respectively. Significant differences were observed 
between the exposure conditions and the PLT group χ2(1, N = 85) = 9.07, p < .05, 
and between the EPR and EPN groups χ2(1, N = 35) = 5.54, p < .05. No 
significant differences were observed between PLT and WL, between EO and 
EPN, or between EPA and EPN. 
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5.3.2.4 Follow-Up Return of Fear 
 Figure 3 presents data on the percentage of participants in each of the 
exposure conditions who met criteria for return of fear based on the reliable 
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change index (Jacobson & Truax, 1991). The percentage of participants meeting 
criteria for return of fear was as follows: EO=0%, EPA=0%, EPN=0% and 
EPR=39%. A chi-square analysis showed this difference was significant χ2(3, N = 
53) = 17.00, p < .001.
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5.4 Moderator Analyses 
No significant interactions were observed between any of the potential 
moderators and medication attribution factors. These findings suggest that the 
deleterious effects of medication attributions were not moderated by age, gender, 
marital status, ethnicity, or diagnostic status. 
5.5 Mediation Analyses 
5.5.1 Step 1: Effect of Treatment on the Mediator 
In Step 1 we entered the scores on the Treatment Gain Attribution 
Questionnaire (Medication) as the DV and EPR vs. EPN as the grouping factor. 
Results indicated that the EPR group made significantly greater attributions to the 
positive effects of the medication compared to the EPN group, F(1, 28) = 159.72, 
p<.000. 
5.5.2 Step 2: Effect of Treatment on Outcome 
In Step 2 we entered the residualized change scores of peak fear from 
Post- to Follow-up during BAT 1 as the DV and EPR vs. EPN as the grouping 
factor. Results indicated that the EPR group showed significantly less 
improvement compared to the EPN group, F(1, 32) = 14.95, p<.001. 
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5.5.3 Step 3: Effect of the Mediator on Outcome 
Next, in Step 3 we tested the effect of the mediator on outcome by 
regressing the residualized change scores of peak fear from Post- to Follow-up 
during BAT 1 on the scores from the Treatment Gain Attribution Questionnaire 
(Medication). The results showed that the medication attributions significantly 
predicted outcome, F(2, 45) = 7.01, p<.01. 
5.5.4 Step 4: Effect of Treatment after Controlling for the Mediator 
Finally, in Step 4 we tested the effect of treatment after controlling for 
medication attributions by entering the residualized change scores of peak fear 
from Post- to Follow-up during BAT 1 as the DV, EPR vs. EPN as the grouping 
factor, and the scores from the Treatment Gain Attribution Questionnaire 
(Medication) as a covariate. As predicted, the effects of treatment were no longer 
significant (p>.05). By controlling for medication attributions the percent variance 
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Percentage of variance in fear reduction accounted for by treatment before and 
after controlling for medication attributions and pre- to post- residualized change 
scores. 
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CHAPTER 6: DISCUSSION 
Studies suggest that anxiety disorder patients who receive combined 
exposure-based and pharmacological treatment are at higher risk of relapsing if 
they discontinue their medication than if they receive CBT alone (Barlow, 
Gorman, Shear, & Woods, 2000). One reason may be that patients attribute their 
treatment gains to the positive effects of medication. In this way they learn 
conditional safety – I’m safe as long as I take my medication. The primary aim of 
the current study was to investigate the possible deleterious effects of these 
medication facilitation attributions on fear reduction during exposure-based 
treatment. Participants (N = 95) displaying marked claustrophobic fear were 
randomly assigned to 1 of 6 conditions: (a) Exposure Only (EO), (b) Exposure + 
Pill Placebo + Arousal Instruction (EPA: medication interference), (c) Exposure + 
Pill Placebo + Neutral Instruction (EPN), (d) Exposure + Pill Placebo + 
Relaxation Instruction (EPR: medication facilitation), (e) credible psychological 
placebo treatment (PLT), or (f) wait-list (WL).  Medication attributions were 
manipulated after the posttreatment assessment thereby isolating the effects of 
attributions at follow-up and ruling out a straightforward placebo effect. 
Consistent with prediction belief in medication facilitation interfered with fear 
reduction at follow-up. However, contrary to prediction belief in medication 
interference did not enhance outcome at follow-up. The effect of taking 
medication with a neutral attribution had no effect on outcome. The placebo 
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group outperformed waitlist at posttreatment but not at follow-up. The exposure 
conditions did not outperform placebo at posttreatment but did at follow-up.  
The waitlist condition showed steady improvement over the post- and 
follow-up assessments and is consistent with previous findings (Powers, Smits, & 
Telch, 2004).  The waitlist condition provided a control for the effects of time and 
repeated assessments. The high performance among those participants in the 
placebo treatment condition at posttreatment and poor outcome at follow-up have 
at least two explanations possible. First, the placebo treatment device may have 
actually induced relaxation at posttreatment. However, the device was set at a 
frequency that is not consistent with relaxation according to previous research 
(Seiver, 2000). Second, there may have been a straightforward placebo effect due 
to the fact that these participants believed the flashing lights and sounds would 
induce relaxation at the posttreatment assessment followed by no such relaxation 
induction at the follow-up assessment. These findings are consistent with other 
studies from our laboratory (Powers, Smits, & Telch, 2004; Wolitzky & Telch, 
2004) and highlight the importance of inclusion of such comparison conditions to 
control for the effects of time, repeated assessment, and expectancy. 
Contrary to prediction the belief in medication interference (EPA) did not 
result in greater fear reduction. The manipulation check showed that although the 
EPA condition rated the harmful effects of medication higher than the other 
exposure conditions, they did not rate the helpful effects of treatment higher. This 
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may represent a ceiling effect as both conditions rated treatment as highly 
effective. The findings suggest that attempts to augment exposure via concurrent 
administration of a stimulant may not succeed if the proposed mechanism is to 
enhance a belief in medication interference. As these participants did not receive 
an active medication it remains unclear to what extent concurrent stimulant 
administration would enhance fear reduction through other mechanisms. 
Consistent with prediction enhancing a medication facilitation attribution 
(EPR) did interfere with fear reduction. Barlow et al. (2000) found a higher rate of 
relapse among patients who were on active medication while they received CBT 
for panic disorder when they later discontinued their medication than those who 
received CBT alone. Likewise, in a correlation study Biondi and Picardi (2003) 
found that 60% of patients who made positive attributions about medications 
during panic treatment relapsed compared to 0% of those who attributed their 
improvement to internal factors. This randomized clinical trial provides further 
support that making a positive attribution about medication during exposure 
treatment is a negative prognostic factor for outcome. During debriefing, 
participants reported that once they learned they had received a medication that 
facilitated their improvement, they were concerned about the upcoming follow-up 
assessment. They didn’t seem to care how the “medication” had impacted their 
past but rather the implications for their future experiences in claustrophobic 
situations.  
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Contrary to prediction the exposure-based treatment did not significantly 
improve claustrophobic behaviors according to the Claustrophobic Behaviors 
Questionnaire. It is likely that this was due to the relatively short follow-up 
period. It may take more time to observe such changes. However, the primary aim 
of this study was not to assess the efficacy of claustrophobic exposure. In 
addition, analysis of the CBQ showed limited variability and a low baseline for 
the behaviors measured (i.e. Riding in the backseat of a car in the middle of two 
people). Also, the current CBQ reads, “Please rate the number of times you have 
engaged in the following behaviors over the previous week including today.” The 
measure may be improved by increasing the time sample to, “over the previous 
month”. During debriefing, patients largely reported that they were not sure how 
much the treatment would later impact their lives as they had not yet encountered 
claustrophobic situations. Later email correspondence with a limited number of 
participants suggested that they had in fact confronted more claustrophobic 
situation based on their participation. However, this sample is biased as it only 
included those who contacted us to thank us for participation. 
The clinical implications of these findings suggest the importance of 
assessing attributions during exposure-based treatment of anxiety disorders. In 
practice we often ask three questions, (a) On a scale of 0 to 100%, how much 
improvement have you noticed in your symptoms?, (b) How much of this 
improvement do you feel is due to the medication?, and (c) How much of this 
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improvement do you feel is due to the treatment or your own efforts? The findings 
from this study suggest that the most effective intervention is to reduce the 
medication facilitation attributions (question b) rather than attempt to raise 
internal attributions by focusing on medication interference attributions (question 
c). One method that has proven effective is to conduct a slow taper off 
medications and to reapply CBT emphasizing interoceptive exposures and 
cognitive restructuring during the taper (see Figure; Otto, Jones, Craske, & 
Barlow, 1996; Otto, Pollack, & Barlow, 1995; Otto, Pollack, Sachs, Reiter, 
Meltzer-Brody, & Rosenbaum, 1993; Whittal, Otto, & Hong, 2001).  
 
TAU=Treatment as Usual + Slow Taper 



















For example, Otto et al. (1993) randomized 33 outpatients who had received a 
minimum of 6 months of benzodiazepine treatment for panic disorder to one of 
two taper conditions: a slow taper condition alone or a slow taper condition 
combined with 10 weeks of group cognitive-behavioral therapy. Patients who 
received CBT during the slow medication taper were more successful than 
patients who were in the slow taper only group (Otto et al., 1993). More 
specifically, 25% of those in the slow taper condition were successful compared 
to 76% in the slow taper plus CBT condition. At a 3-month follow-up, 77% of the 
patients in the CBT program remained medication free. As patients continue to 
apply exposure while going off of their medications they learn unconditional 
safety – I’m safe even when I don’t take my medication. This medication 
discontinuation protocol has also been applied to SSRI treatment of panic 
disorder. In a case series Whittal et al. (2001) described the successful treatment 
of 8 participants who were being treated with an SSRI who wanted to discontinue 
their medication in the context of CBT. However, these studies do not address 
relapse prevention among patients who desire to stay on medication during CBT 
with a plan to later discontinue medication. If patients prefer to initiate or 
continue medication during CBT, relapse may continue to be a problem (Barlow 
et al. 2000). Future studies may explore the advantage of integrating the 
medication discontinuation strategies with such patients. In addition, these studies 
do not suggest why a slow taper and reapplication of CBT result in superior 
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outcome. Future studies may help determine if this slow taper/exposure 
combination changes medication attributions or operates through some other 
mechanism. Telch (in press) has also suggested that a single case double blind 
alternating treatment design helps patients overcome benzodiazepine attributions.  
A given patient is randomized to either placebo or benzodiazepine and they rate 
their anxiety each day. The therapist and patient then break the blind to determine 
how helpful the medication has been.  
Several limitations deserve comment. First, although we used a stringent 
two-stage screening procedure to ensure that study participants displayed marked 
phobicity (our sample represented the top 1% on indices of claustrophobic fear 
and avoidance), 24% of the participants did not meet DSM-IV criteria for specific 
phobia. Among those who did not, all met full DSM-IV criteria with the 
exception of Criterion E (i.e., the person must experience significant interference 
in social, academic, or work functioning or experience marked distress about 
having the phobia). Therefore, the current study represents neither a strictly 
clinical nor analogue design. The current study, however, was designed to test the 
role of attributions about medication in the context of CBT rather than to 
determine the efficacy of exposure-based treatment. This hybrid design was 
selected to further investigate the potential moderating effects of clinical status. 
We examined empirically whether meeting all DSM-IV criteria moderated 
treatment outcome and it did not. This finding is consistent with our previous 
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study (Powers, Smits, & Telch, 2004) and provides additional evidence that those 
presenting with marked fear without significant life interference respond no 
differently to the treatments relative to those who are above diagnostic threshold. 
Second, although the EPA condition rated the harmful effects of medication 
higher than the other exposure conditions, they did not rate the helpful effects of 
treatment higher. Finally, the follow-up period of 1 week was too brief to make 
inferences about the stability of the attribution effects over the long term. 
Future directions include identifying methods of reducing external 
attributions and enhancing internal attributions. It appears that a slow taper off 
medications while reapplying exposure may be effective in preventing relapse. It 
would be interesting to know if this effect is mediated by medication attributions. 
One method of enhancing fear reduction  includes anti-phobic strategies 
(Wolitzky & Telch, 2004). Sloan and Telch (2001) proposed that the mere act of 
engaging in safety behaviors may directly activate the alarm system - much like 
there are direct neural pathways for sensorimotor information to travel to the 
limbic system (Ledoux, 1998). Hence, they hypothesized that actions that are not 
consistent with threat transmission may facilitate fear reduction achieved with 
exposure-based practice. Such inclusion of anti-phobic strategies involves more 
than eliminating safety behaviors; this is the active programming of behaviors that 
challenge the notion that one must be “careful” in a phobic situation. Preliminary 
evidence suggests that the inclusion of anti-phobic strategies in exposure-based 
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treatment protocols may indeed enhance outcome. For example, Wolitzky and 
Telch (2004) reported that participants with height phobia who employed anti-
phobic actions such as jogging towards the railing, and making oneself dizzy near 
the railing, showed greater fear reduction compared to participants who 
completed exposure exercises as usual. From a learning perspective, anti-phobic 
strategies may function as “excitors” that increase the over prediction of the US 
thus resulting in a magnified discrepancy between the expectation of negative 
outcomes and the actual (“relatively safe”) outcome achieved in exposure 
(Bouton, Mineka, & Barlow, 2001). Therefore, it is likely that the error correction 
and learning should also be magnified. However, it may also be the case that anti-
phobic strategies enhance internal attributions – I must be safe if I can stay in the 
claustrophobic space even while taking caffeine. Although this study suggests that 
medication attributions are one path to potential relapse, it is likely that there are 
additional reasons. One such hypothesis is that what is learned on medication may 
not transfer to the non-drug state due to context effects (Powers, Smits, & Otto, in 
press). One solution may be pharmacological augmentation during exposure. 
Procedurally, exposure-based CBT is very similar to animal models of extinction 
of conditioned fears, and recent advances in animal research have identified 
pharmacological agents that appear to both accelerate and consolidate extinction 
learning (Cain, Blouin, & Barad, 2004; Davis, 2002). For example, administration 
of Yohimbine (an α2-receptor antagonist) during extinction trials accelerates fear 
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reduction and also may convert ineffective exposures to successful ones (Cain, 
Blouin, & Barad, 2004).  In a series of studies, Cain et al. (2004) found that 
systemic administration (injection) of Yohimbine (5mg/kg) reduced the number 
of trials needed to extinguish fear in conditioned mice from 30 trials to only 5 
trials. The facilitative effects of Yohimbine on fear reduction were also evident 
when the mice were later tested without the drug. Even more interesting, 
Yohimbine treated mice appeared to be protected from the negative effects of 
spacing extinction trials (20-minute intertrial intervals) compared to placebo 
treated mice. The effect of Yohimbine during exposure in humans has not yet 
been investigated.  
In conclusion, results showed that a medication facilitation attribution
(EPR: relaxing/sedating instruction) interfered with fear reduction. Contrary to
prediction, a medication interference attribution (EPA: arousal instruction) did
not enhance fear reduction compared to the other exposure conditions. The
deleterious effects of the relaxation instructions were fully mediated by
attributions about the helpful effects of the medication reducing the variance
accounted for by treatment from 30% to 7%. Findings suggest the importance of
assessing attributions during combined exposure-based and pharmacological
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